Skip to Main Content
Directory of Faculty Research Interests
YSM Home

INFORMATION FOR

DownloadHi-Res Photo

Cary Gross, MD

Professor of Medicine (General Medicine) and of Epidemiology (Chronic Diseases); Founder and Director, Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale School of Medicine; Director, Adult Primary Care Center, Quality Improvement; Director, National Clinician Scholars Program; Associate Editor, Department of Medicine

Contact Information

Cary Gross, MD

Mailing Address

  • General Internal Medicine

    PO Box 208056, 333 Cedar Street

    New Haven, CT 06520-8056

    United States

COPPER Center
Download CV

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

As Director of Yale's Cancer Outcomes Public Policy & Effectiveness Research (COPPER; http://copper.yale.edu/).Center, the over-arching theme of my work is the disconnect between evidence generated from clinical research and the needs of members of patients in the "real-world" setting, outside of clinical trials. Ongoing investigations focus on the comparative effectiveness of different approaches to cancer screening and treatment, the complex interplay of factors affecting the value of cancer care, and the abandonment of low-value approaches to cancer care. Bioethics and research integrity are also a major interest; my work has focused on the scope and impact of financial conflicts, as well as identifying and overcoming barriers to sharing research data as part of the YODA project at Yale (http://yoda.yale.edu/ )

Specialized Terms: Cancer policy; Health policy; Comparative effectiveness; Cancer outcomes; Research ethics and integrity

Extensive Research Description

I am the Director of the COPPER Center at Yale, which aims to improve cancer care and to decrease the burden of cancer on individual patients and society, and to increase equity and patient-centeredness in cancer care. The Center is comprised of researchers and clinicians from across the Yale Schools of Medicine (General Medicine, Geriatrics, Oncology, Radiation Oncology, Dermatology, and Pediatrics), Public Health, and Nursing. We also provide training and mentorship to the next generation of cancer policy and outcomes researchers. Please see the COPPER website for a full description of the team and our work (http://copper.yale.edu/).

I have received NIH-funding from 2002 through the present time, with grants supporting the investigation of barriers to clinical trial enrollment, the impact of non-cancer illnesses on older persons with cancer, and the dissemination of new approaches to cancer screening and treatment into clinical practice.Currently, my collaborators and I are recipients of an NCI Provocative Questions grant, which aims to apply the concept of “social contagion” to cancer practice, shedding new light on the role of physicians and physician patient-sharing networks in the adoption of unproven technologies and the abandonment of proven ineffective treatments in cancer care.

Our recent grant through the American Cancer Society explores trends in breast cancer screening from both a clinical and policy perspective. Partnering with the Blue Cross Blue Shield Alliance for Health Research, we are assessing the association between state breast density legislation and the adoption of new breast imaging modalities, as well as evaluating the effectiveness of these newer approaches to breast cancer screening.

I am particularly interested in cancer in older persons. Cancer is an aging-related disease, and elderly cancer patients tend to have worse outcomes than their younger counterparts. This is likely due, at least in part, to the myriad of non–cancer problems that tend to accrue with age. To provide greater clarity for patient and provider decision-making, we are exploring the manner in which non–cancer chronic illnesses and geriatric syndromes affect the care and outcomes of older patients with colorectal cancer. We are using a large population-based cohort of patients with cancer derived from administrative data, and in a separate study, COPPER is participating in a prospective cohort study of older patients with cancer as part of the Cancer in Aging Research Group (CARG: http://www.mycarg.org/home).

Coauthors

Research Interests

Chronic Disease; Epidemiology; Health Policy; Internal Medicine; Ethics, Research

Selected Publications

  • Artificial Intelligence in Breast Cancer ScreeningPotnis K, Ross J, Aneja S, Gross C, Richman I. Artificial Intelligence in Breast Cancer Screening JAMA Internal Medicine 2022, 182: 1306-1312. PMID: 36342705, DOI: 10.1001/jamainternmed.2022.4969.
  • Parent Priorities in End-of-Life Care for Children with Cancer (CO202C)Ananth P, Lindsay M, Mun S, De Oliveira S, Pitafi S, Gross C, Boyden J, Feudtner C, Wolfe J. Parent Priorities in End-of-Life Care for Children with Cancer (CO202C) Journal Of Pain And Symptom Management 2022, 63: 1064. DOI: 10.1016/j.jpainsymman.2022.04.011.
  • MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENINGLeapman M, Long J, Wang R, Sprenkle P, Ma X, Gross C. MP53-11 FOUR KALLIKREIN PANEL TESTING AMONG MEDICARE BENEFICIARIES UNDERGOING PROSTATE CANCER SCREENING Investigative Urology 2022, 207: e899. DOI: 10.1097/ju.0000000000002628.11.
  • Parent Priorities in End-of-Life Care for Children with CancerAnanth P, Mun S, Mun S, Lindsay M, De Oliveira S, Pitafi S, Ma X, Gross C, Boyden J, Boyden J, Feudtner C, Feudtner C, Wolfe J, Wolfe J. Parent Priorities in End-of-Life Care for Children with Cancer Journal Of Pain And Symptom Management 2022, 63: 885. DOI: 10.1016/j.jpainsymman.2022.02.087.
  • Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.6_suppl.300.
  • Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.
  • Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.Spees L, Wheeler S, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 87-87. DOI: 10.1200/jco.2020.39.28_suppl.87.
  • Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer.Adelson K, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Canavan M. Differences by race in systemic oncologic end-of-life (EOL) care among patients with cancer. Journal Of Clinical Oncology 2021, 39: 137-137. DOI: 10.1200/jco.2020.39.28_suppl.137.
  • Trends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data.Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Trends in end-of- life (EOL) systemic oncologic treatment in contemporary clinical practice: Insights from real-world data. Journal Of Clinical Oncology 2021, 39: 253-253. DOI: 10.1200/jco.2020.39.28_suppl.253.
  • PD46-08 MEDIATORS OF RACIAL DISPARITY IN THE USE OF PROSTATE MRILeapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. PD46-08 MEDIATORS OF RACIAL DISPARITY IN THE USE OF PROSTATE MRI Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002060.08.
  • Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysisAxson S, Mello MM, Lincow D, Yang C, Gross C, Ross JS, Miller J. Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis BMJ Open 2021, 11: e053248. PMID: 34281933, PMCID: PMC8291313, DOI: 10.1136/bmjopen-2021-053248.
  • Building a Digital Health Risk Calculator for Older Women with Early-Stage Breast CancerAbujarad F, Wang S, Ulrich D, Mougalian S, Killelea B, Fraenkel L, Gross C, Evans S. Building a Digital Health Risk Calculator for Older Women with Early-Stage Breast Cancer 2021, 12780: 389-402. DOI: 10.1007/978-3-030-78224-5_27.
  • Relative risks of Covid-19 fatality between the first and second waves of the pandemic in Ontario, CanadaHsu SH, Chang SH, Gross C, Wang SY. Relative risks of Covid-19 fatality between the first and second waves of the pandemic in Ontario, Canada International Journal Of Infectious Diseases 2021, 109: 189-191. PMID: 34216734, PMCID: PMC8245301, DOI: 10.1016/j.ijid.2021.06.059.
  • Abstract 898: Survival for patients with early-onset colorectal cancer - An overall survival analysis from the National Cancer Database, 2004-2015Cheng E, Cheng E, Blackburn H, Ng K, Ng K, Spiegelman D, Irwin M, Ma X, Gross C, Tabung F, Tabung F, Giovannucci E, Giovannucci E, Kunz P, Llor X, Billingsley K, Meyerhardt J, Meyerhardt J, Ahuja N, Fuchs C. Abstract 898: Survival for patients with early-onset colorectal cancer - An overall survival analysis from the National Cancer Database, 2004-2015 Cancer Research 2021, 81: 898-898. DOI: 10.1158/1538-7445.am2021-898.
  • Incarceration and Cancer-Related Outcomes (ICRO) study protocol: using a mixed-methods approach to investigate the role of incarceration on cancer incidence, mortality and quality of carePuglisi L, Halberstam AA, Aminawung J, Gallagher C, Gonsalves L, Schulman-Green D, Lin HJ, Metha R, Mun S, Oladeru OT, Gross C, Wang EA. Incarceration and Cancer-Related Outcomes (ICRO) study protocol: using a mixed-methods approach to investigate the role of incarceration on cancer incidence, mortality and quality of care BMJ Open 2021, 11: e048863. PMID: 34035109, PMCID: PMC8154989, DOI: 10.1136/bmjopen-2021-048863.
  • How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.
  • Adoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer.Jairam V, Pasha S, Pasha S, Soulos P, Soulos P, Goldberg S, Yu J, Yu J, Decker R, Gross C, Park H. Adoption of consolidative durvalumab among patients with locally advanced non-small cell lung cancer. Journal Of Clinical Oncology 2021, 39: e20550-e20550. DOI: 10.1200/jco.2021.39.15_suppl.e20550.
  • Mediators of racial disparity in the use of prostate MRI.Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. Mediators of racial disparity in the use of prostate MRI. Journal Of Clinical Oncology 2021, 39: 6554-6554. DOI: 10.1200/jco.2021.39.15_suppl.6554.
  • Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer.Takvorian S, Parikh R, Vader D, Wileyto E, Clark A, Lee D, Goyal G, Rocque G, Dotan E, Geynisman D, Phull P, Spiess P, Kim R, Davidoff A, Gross C, Miksad R, Calip G, Shulman L, Mamtani R, Hubbard R. Impact of COVID-19 pandemic on time to treatment initiation for patients with advanced cancer. Journal Of Clinical Oncology 2021, 39: 1528-1528. DOI: 10.1200/jco.2021.39.15_suppl.1528.
  • Uptake and effectiveness of checkpoint inhibitor therapy among trial-ineligible patients with advanced solid malignancies.Parikh R, Min E, Wileyto E, Riaz F, Gross C, Cohen R, Hubbard R, Long Q, Mamtani R. Uptake and effectiveness of checkpoint inhibitor therapy among trial-ineligible patients with advanced solid malignancies. Journal Of Clinical Oncology 2021, 39: e18595-e18595. DOI: 10.1200/jco.2021.39.15_suppl.e18595.
  • YIA21-001: A Modified Delphi Study to Refine Measures of End-of-Life Care Quality for Children with CancerAnanth P, Mun S, Reffat N, Kang S, Pitafi S, Ma X, Gross C, Wolfe J. YIA21-001: A Modified Delphi Study to Refine Measures of End-of-Life Care Quality for Children with Cancer Journal Of The National Comprehensive Cancer Network 2021, 19: yia21-001. DOI: 10.6004/jnccn.2020.7751.
  • Abstract PS8-03: Inflammation and coagulation biomarkers associated with physical resilience in older women receiving chemotherapy for early breast cancerSedrak M, Sun C, Muss H, Freedman R, Magnuson A, Gross C, Tew W, Klepin H, Wildes T, Dotan E, O'Connor T, Fenton M, Sharma R, Chapman A, Owusu C, Chow S, Kim H, Katheria V, LaBarge M, Dale W, Armenian S, Neuhausen S, Cohen H. Abstract PS8-03: Inflammation and coagulation biomarkers associated with physical resilience in older women receiving chemotherapy for early breast cancer Cancer Research 2021, 81: ps8-03-ps8-03. DOI: 10.1158/1538-7445.sabcs20-ps8-03.
  • Association Between Sexual Orientation, Mistreatment, and Burnout Among US Medical StudentsSamuels EA, Boatright DH, Wong AH, Cramer LD, Desai MM, Solotke MT, Latimore D, Gross CP. Association Between Sexual Orientation, Mistreatment, and Burnout Among US Medical Students JAMA Network Open 2021, 4: e2036136. PMID: 33528552, PMCID: PMC7856540, DOI: 10.1001/jamanetworkopen.2020.36136.
  • Association Between Prophylactic Cranial Irradiation and Improved Overall Survival in Small Cell Lung CancerYang D, Park H, Jairam V, Decker R, Chiang A, Gross C, Yu J. Association Between Prophylactic Cranial Irradiation and Improved Overall Survival in Small Cell Lung Cancer International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e106. DOI: 10.1016/j.ijrobp.2020.07.1223.
  • Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer PatientsGao S, Dosoretz A, Shafman T, Gross C, Yu J, Meadows H, Decker R, Mak R, Kann B. Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e90. DOI: 10.1016/j.ijrobp.2020.07.1190.
  • Post-Operative Radiation Therapy for Non-Small Cell Lung Cancer: A Comparison of Radiation Therapy TechniquesJairam V, Pasha S, Pasha S, Soulos P, Soulos P, Gross C, Yu J, Yu J, Park H, Decker R. Post-Operative Radiation Therapy for Non-Small Cell Lung Cancer: A Comparison of Radiation Therapy Techniques International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e130. DOI: 10.1016/j.ijrobp.2020.07.1276.
  • Endometrial Sampling for Preoperative Diagnosis of Uterine LeiomyosarcomaKho R, Desai V, Schwartz P, Wright J, Gross C, Hutchison L, Boscoe F, Lin H, Xu X. Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma Journal Of Minimally Invasive Gynecology 2020, 27: s129. DOI: 10.1016/j.jmig.2020.08.232.
  • The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM).Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2020, 38: 2-2. DOI: 10.1200/jco.2020.38.29_suppl.2.
  • The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC).Gross C, Meyer C, Ogale S, Kent M, Wong W. The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC). Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.29_suppl.89.
  • The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization.Wong W, Sheinson D, Ogale S, Flores C, Gross C. The association between Medicare’s next generation sequencing (NGS), national coverage decision (NCD), and NGS utilization. Journal Of Clinical Oncology 2020, 38: 98-98. DOI: 10.1200/jco.2020.38.29_suppl.98.
  • Is there variation in private payor payments to cancer surgeons? A cross-sectional study in the USABongiovanni T, Kim SP, Kim A, Killelea B, Gross C. Is there variation in private payor payments to cancer surgeons? A cross-sectional study in the USA BMJ Open 2020, 10: e035438. PMID: 33020076, PMCID: PMC7537435, DOI: 10.1136/bmjopen-2019-035438.
  • What Defines High Quality End-of-Life Care for Children with Cancer? A Stakeholder-Driven Qualitative Study (GP706)Ananth P, Mun S, Reffat N, Li R, Sedghi T, Bilodeau M, Snaman J, Gross C, Ma X, Wolfe J. What Defines High Quality End-of-Life Care for Children with Cancer? A Stakeholder-Driven Qualitative Study (GP706) Journal Of Pain And Symptom Management 2020, 60: 249. DOI: 10.1016/j.jpainsymman.2020.04.129.
  • The adoption of immune checkpoint inhibitors and patterns of care at the end of life.Riaz F, Gan G, Li F, Davidoff A, Adelson K, Presley C, Adamson B, Shaw P, Parikh R, Mamtani R, Gross C. The adoption of immune checkpoint inhibitors and patterns of care at the end of life. Journal Of Clinical Oncology 2020, 38: 12027-12027. DOI: 10.1200/jco.2020.38.15_suppl.12027.
  • Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy.Yang D, Jairam V, Park H, Decker R, Chiang A, Gross C, Yu J. Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy. Journal Of Clinical Oncology 2020, 38: e19309-e19309. DOI: 10.1200/jco.2020.38.15_suppl.e19309.
  • Temporal trends in opioid prescribing patterns among oncologists in the Medicare population.Jairam V, Yang D, Pasha S, Soulos P, Gross C, Yu J, Park H. Temporal trends in opioid prescribing patterns among oncologists in the Medicare population. Journal Of Clinical Oncology 2020, 38: 12022-12022. DOI: 10.1200/jco.2020.38.15_suppl.12022.
  • The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM).Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM). Journal Of Clinical Oncology 2020, 38: e19367-e19367. DOI: 10.1200/jco.2020.38.15_suppl.e19367.
  • Aggressive care at end-of-life in the Veteran’s Health Administration versus fee-for-service Medicare among patients with advanced lung cancer.Presley C, Kaur K, Han L, Soulos P, Zhu W, Corneau E, O'Leary J, Chao H, Shamas T, Rose M, Lorenz K, Levy C, Mor V, Gross C. Aggressive care at end-of-life in the Veteran’s Health Administration versus fee-for-service Medicare among patients with advanced lung cancer. Journal Of Clinical Oncology 2020, 38: 12025-12025. DOI: 10.1200/jco.2020.38.15_suppl.12025.
  • Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.
  • Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies.Parikh R, Cohen R, Min E, Wileyto E, Riaz F, Gross C, Long Q, Mamtani R. Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies. Journal Of Clinical Oncology 2020, 38: e19316-e19316. DOI: 10.1200/jco.2020.38.15_suppl.e19316.
  • Assessment of the Prevalence of Medical Student Mistreatment by Sex, Race/Ethnicity, and Sexual OrientationHill KA, Samuels EA, Gross CP, Desai MM, Zelin N, Latimore D, Huot SJ, Cramer LD, Wong AH, Boatright D. Assessment of the Prevalence of Medical Student Mistreatment by Sex, Race/Ethnicity, and Sexual Orientation JAMA Internal Medicine 2020, 180: 653-665. PMID: 32091540, PMCID: PMC7042809, DOI: 10.1001/jamainternmed.2020.0030.
  • Abstract P6-12-09: My PROfile: A web-based tool to assess patient reported outcomes (PROs) in women with metastatic breast cancer (MBC): Preliminary resultsMougalian S, Canavan M, Capasso R, Aminawung J, Presley C, Gross C. Abstract P6-12-09: My PROfile: A web-based tool to assess patient reported outcomes (PROs) in women with metastatic breast cancer (MBC): Preliminary results Cancer Research 2020, 80: p6-12-09-p6-12-09. DOI: 10.1158/1538-7445.sabcs19-p6-12-09.
  • Abstract P5-07-08: Development and validation of the “radiotherapy for older women” risk calculatorWang S, Mougalian S, Killelea B, Herrin J, Fraenkel L, Gross C, Evans S. Abstract P5-07-08: Development and validation of the “radiotherapy for older women” risk calculator Cancer Research 2020, 80: p5-07-08-p5-07-08. DOI: 10.1158/1538-7445.sabcs19-p5-07-08.
  • Abstract PD10-10: Factors associated with decreased relative dose intensity in older adults with early-stage breast cancer receiving chemotherapySedrak M, Sun C, Magnuson A, Muss H, Freedman R, Gross C, Tew W, Klepin H, Wildes T, Dotan E, O'Connor T, Cohen H, Kim H, Katheria V, Jayani R, Arsenyan A, Levi A, Charles K, Hurria A, Dale W. Abstract PD10-10: Factors associated with decreased relative dose intensity in older adults with early-stage breast cancer receiving chemotherapy Cancer Research 2020, 80: pd10-10-pd10-10. DOI: 10.1158/1538-7445.sabcs19-pd10-10.
  • What Defines High Quality End-of-Life Care for Children with Cancer? A Stakeholder-Driven Qualitative Study (FR481C)Ananth P, Li R, Reffat N, Mun S, Sedghi T, Bilodeau M, Gross C, Ye X, Snaman J, Wolfe J. What Defines High Quality End-of-Life Care for Children with Cancer? A Stakeholder-Driven Qualitative Study (FR481C) Journal Of Pain And Symptom Management 2020, 59: 487-488. DOI: 10.1016/j.jpainsymman.2019.12.186.
  • “Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancerWang SY, Abujarad F, Chen T, Evans SB, Killelea BK, Mougalian SS, Fraenkel L, Gross C. “Radiotherapy for older women (ROW)”: A risk calculator for women with early-stage breast cancer Journal Of Geriatric Oncology 2019, 11: 850-859. PMID: 31899199, PMCID: PMC7263974, DOI: 10.1016/j.jgo.2019.12.010.
  • Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United StatesHuntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States Blood 2019, 134: 797-797. DOI: 10.1182/blood-2019-122054.
  • Moving to Bundled Payments: Costs of Lung Cancer ResectionsBongiovanni T, Jean R, Xu X, Soulos P, Herrin J, Kim A, Gross C. Moving to Bundled Payments: Costs of Lung Cancer Resections Journal Of The American College Of Surgeons 2019, 229: e209. DOI: 10.1016/j.jamcollsurg.2019.08.1434.
  • 1558P Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)Cohen A, Neri B, Adamson B, Scanlon C, Gross C, Meropol N, Miksad R. 1558P Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) Annals Of Oncology 2019, 30: v642. DOI: 10.1093/annonc/mdz260.080.
  • Utilization and costs of breast cancer screening for women in their 40s in a privately insured U.S. population.Kunst N, Long J, Xu X, Busch S, Richman I, Kyanko K, Gross C. Utilization and costs of breast cancer screening for women in their 40s in a privately insured U.S. population. Journal Of Clinical Oncology 2019, 37: 105-105. DOI: 10.1200/jco.2019.37.27_suppl.105.
  • Effects of rising drug costs on efforts to control overall cost at a large academic cancer center.Adelson K, Canavan M, Supalla S, Sedghi T, Chaudhry B, Sinanis N, Gross C. Effects of rising drug costs on efforts to control overall cost at a large academic cancer center. Journal Of Clinical Oncology 2019, 37: 2-2. DOI: 10.1200/jco.2019.37.27_suppl.2.
  • Adoption of Digital Breast Tomosynthesis in Clinical PracticeRichman IB, Hoag JR, Xu X, Forman HP, Hooley R, Busch SH, Gross CP. Adoption of Digital Breast Tomosynthesis in Clinical Practice JAMA Internal Medicine 2019, 179: 1292-1295. PMID: 31233086, PMCID: PMC6593646, DOI: 10.1001/jamainternmed.2019.1058.
  • An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer PatientsGao S, Kann B, Dosoretz A, Shafman T, Gross C, Yu J, Decker R. An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s145-s146. DOI: 10.1016/j.ijrobp.2019.06.146.
  • Predictors of Toxicity from Stereotactic Body Radiotherapy (SBRT) for Lung Tumors Ultra-Central or Central to Heart, Esophagus, or Proximal Bronchial TreeChang E, Decker R, Hu X, Yu J, Gross C, Lester-Coll N. Predictors of Toxicity from Stereotactic Body Radiotherapy (SBRT) for Lung Tumors Ultra-Central or Central to Heart, Esophagus, or Proximal Bronchial Tree International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e499-e500. DOI: 10.1016/j.ijrobp.2019.06.1413.
  • The Effect of Race and Decision Aids on Provider Recommendation for Prostate Cancer Treatment Planning: A Randomized StudyMahal A, Mahal B, Kim S, Singh R, Green A, Nguyen P, Gross C, Yu J. The Effect of Race and Decision Aids on Provider Recommendation for Prostate Cancer Treatment Planning: A Randomized Study International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s220. DOI: 10.1016/j.ijrobp.2019.06.306.
  • Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment.Adamson B, Cohen A, Estevez M, Magee K, Williams E, Gross C, Meropol N, Davidoff A. Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment. Journal Of Clinical Oncology 2019, 37: lba1-lba1. DOI: 10.1200/jco.2019.37.18_suppl.lba1.
  • Impact of morcellation on mortality in women with unexpected uterine cancer who underwent hysterectomy and myomectomyXu X, Wright J, Gross C, Lin H, Boscoe F, Hutchison L, Schwartz P, Desai V. Impact of morcellation on mortality in women with unexpected uterine cancer who underwent hysterectomy and myomectomy Gynecologic Oncology 2019, 154: 170-171. DOI: 10.1016/j.ygyno.2019.04.399.
  • Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.
  • Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.Leapman M, Presley C, Zhu W, Soulos P, Adelson K, Boffa D, Gross C. Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2019, 37: 9059-9059. DOI: 10.1200/jco.2019.37.15_suppl.9059.
  • Abandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care.Xu X, Soulos P, Herrin J, Wang S, Pollack C, Evans S, Gross C, Yu J. Abandonment trajectories of conventionally fractionated adjuvant radiotherapy in breast cancer care. Journal Of Clinical Oncology 2019, 37: 531-531. DOI: 10.1200/jco.2019.37.15_suppl.531.
  • Impact of an oncology urgent care clinic on emergency department rates.Sedghi T, Canavan M, Gross C, Davidoff A, Gould Rothberg B, Strait M, Sinanis N, Adelson K. Impact of an oncology urgent care clinic on emergency department rates. Journal Of Clinical Oncology 2019, 37: 6615-6615. DOI: 10.1200/jco.2019.37.15_suppl.6615.
  • Understanding cancer care coordination: Opening the black box.Canavan M, Sedghi T, Gross C, Lane S, Bogdan J, Adelson K. Understanding cancer care coordination: Opening the black box. Journal Of Clinical Oncology 2019, 37: e18310-e18310. DOI: 10.1200/jco.2019.37.15_suppl.e18310.
  • Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening.Yang D, Makarov D, Gross C, Yu J. Contemporary changes in localized and metastatic prostate cancer incidence by geographic area following decreased PSA screening. Journal Of Clinical Oncology 2019, 37: 1567-1567. DOI: 10.1200/jco.2019.37.15_suppl.1567.
  • PCN200 MEDICAID EXPANSION AND RACIAL INEQUITIES IN NEXT GENERATION SEQUENCING TESTING IN ONCOLOGYHooley I, Cohen A, Gross C, Williams E, Adamson B. PCN200 MEDICAID EXPANSION AND RACIAL INEQUITIES IN NEXT GENERATION SEQUENCING TESTING IN ONCOLOGY Value In Health 2019, 22: s93. DOI: 10.1016/j.jval.2019.04.322.
  • P78 Treatment-Related Complications of Chemotherapy and Radiotherapy: An Analysis of the Nationwide Emergency Department SampleJairam V, Lee V, Park H, Thomas C, Melnick E, Gross C, Presley C, Adelson K, Yu J. P78 Treatment-Related Complications of Chemotherapy and Radiotherapy: An Analysis of the Nationwide Emergency Department Sample International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e51-e52. DOI: 10.1016/s0360-3016(19)30528-0.
  • MP29-16 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT, INSURANCE STATUS, AND TREATMENT AMONG PATIENTS WITH TESTICULAR CANCERHsiang W, Jemal A, Nguyen K, Shuch B, Park H, Yu J, Gross C, Davidoff A, Leapman* M. MP29-16 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT, INSURANCE STATUS, AND TREATMENT AMONG PATIENTS WITH TESTICULAR CANCER Investigative Urology 2019, 201 DOI: 10.1097/01.ju.0000557551.36748.5c.
  • Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice.Parikh R, Galsky M, Gyawali B, Riaz F, Kaufmann T, Cohen A, Adamson B, Gross C, Meropol N, Mamtani R. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice. Journal Of Clinical Oncology 2019, 37: 395-395. DOI: 10.1200/jco.2019.37.7_suppl.395.
  • Abstract P5-14-06: Prioritization of patient reported outcomes by women with metastatic breast cancerMougalian S, Aminawung J, Presley C, Canavan M, Holland M, Hu X, Gross C. Abstract P5-14-06: Prioritization of patient reported outcomes by women with metastatic breast cancer Cancer Research 2019, 79: p5-14-06-p5-14-06. DOI: 10.1158/1538-7445.sabcs18-p5-14-06.
  • Abstract PD6-07: Trends in the cost of care for breast cancer among women with commercial insuranceRuddy K, Sangaralingham L, Freedman R, Jemal A, Mougalian S, Keegan T, Loprinzi C, Gross C, Henk H, Shah N. Abstract PD6-07: Trends in the cost of care for breast cancer among women with commercial insurance Cancer Research 2019, 79: pd6-07-pd6-07. DOI: 10.1158/1538-7445.sabcs18-pd6-07.
  • Abstract GS6-04: Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): A R01 and BCRF funded prospective multicenter studyHurria A, Magnuson A, Gross C, Tew W, Klepin H, Wildes T, Muss H, Dotan E, Freedman R, O'Connor T, Dale W, Cohen H, Katheria V, Arsenyan A, Levi A, Kim H, Sun C. Abstract GS6-04: Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): A R01 and BCRF funded prospective multicenter study Cancer Research 2019, 79: gs6-04-gs6-04. DOI: 10.1158/1538-7445.sabcs18-gs6-04.
  • Finding the Path: Incorporating Patient Preferences into an Interactive Clinical Pathway Platform (S867)Schulman-Green D, Cherlin E, Capasso R, Mougalian S, Wang S, Gross C, Bajaj P, Eakle K, Adelson K, Patel S. Finding the Path: Incorporating Patient Preferences into an Interactive Clinical Pathway Platform (S867) Journal Of Pain And Symptom Management 2019, 57: 517. DOI: 10.1016/j.jpainsymman.2018.12.317.
  • Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET UtilityHuntington S, Zhu W, Hoag J, Wang R, Zeidan A, Giri S, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A. Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility Blood 2018, 132: 3538-3538. DOI: 10.1182/blood-2018-99-115140.
  • Systemic Therapy with Stereotactic Body Radiation Therapy (SBRT) for Early-Stage Non-Small Cell Lung Carcinoma (NSCLC): A Multi-institutional AnalysisKann B, Miccio J, Stahl J, Verma V, Dosoretz A, Park H, Shafman T, Gross C, Yu J, Decker R. Systemic Therapy with Stereotactic Body Radiation Therapy (SBRT) for Early-Stage Non-Small Cell Lung Carcinoma (NSCLC): A Multi-institutional Analysis International Journal Of Radiation Oncology • Biology • Physics 2018, 102: s10-s11. DOI: 10.1016/j.ijrobp.2018.06.119.
  • Persistent Use of Extended Fractionation Palliative Radiation Therapy for Medicare Beneficiaries with Metastatic Breast Cancer: 2011-2014Yu J, Pollack C, Herrin J, Zhu W, Soulos P, Xu X, Gross C. Persistent Use of Extended Fractionation Palliative Radiation Therapy for Medicare Beneficiaries with Metastatic Breast Cancer: 2011-2014 International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e425. DOI: 10.1016/j.ijrobp.2018.07.1241.
  • Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable CancersJohnson S, Park H, Gross C, Yu J. Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival among Patients with Curable Cancers International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e399-e400. DOI: 10.1016/j.ijrobp.2018.07.1180.
  • Factors Associated With Cancer Disparities Among Low-, Medium-, and High-Income US CountiesO’Connor J, Sedghi T, Dhodapkar M, Kane MJ, Gross CP. Factors Associated With Cancer Disparities Among Low-, Medium-, and High-Income US Counties JAMA Network Open 2018, 1: e183146. PMID: 30646225, PMCID: PMC6324449, DOI: 10.1001/jamanetworkopen.2018.3146.
  • State breast density inform mandate laws and utilization of adjunctive screening tests and cancer detection following screening mammography.Gross C, Hoag J, Hoag J, Xu X, Richman I, Aminawung J, Soulos P, Soulos P, Busch S. State breast density inform mandate laws and utilization of adjunctive screening tests and cancer detection following screening mammography. Journal Of Clinical Oncology 2018, 36: 6579-6579. DOI: 10.1200/jco.2018.36.15_suppl.6579.
  • Early adoption of digital breast tomosynthesis in the United States.Richman I, Hoag J, Busch S, Gross C. Early adoption of digital breast tomosynthesis in the United States. Journal Of Clinical Oncology 2018, 36: e13543-e13543. DOI: 10.1200/jco.2018.36.15_suppl.e13543.
  • Comparative effectiveness of sentinel lymph node biopsy for patients with ductal carcinoma in situ.Wang S, Hung P, Killelea B, Mougalian S, Evans S, Sedghi T, Gross C. Comparative effectiveness of sentinel lymph node biopsy for patients with ductal carcinoma in situ. Journal Of Clinical Oncology 2018, 36: e12602-e12602. DOI: 10.1200/jco.2018.36.15_suppl.e12602.
  • Treatment patterns and survival for hepatocellular carcinoma in USA and Taiwan.Wang S, Lin Y, Lin C, Sedghi T, Hsu S, Kim H, Chou T, Chiu Y, Gross C, Wang J. Treatment patterns and survival for hepatocellular carcinoma in USA and Taiwan. Journal Of Clinical Oncology 2018, 36: e16120-e16120. DOI: 10.1200/jco.2018.36.15_suppl.e16120.
  • Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma.Huntington S, Von Keudell G, Davidoff A, Gross C, Prasad S. Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma. Journal Of Clinical Oncology 2018, 36: 6609-6609. DOI: 10.1200/jco.2018.36.15_suppl.6609.
  • Treatment effect of neoadjuvant endocrine therapy compared to neoadjuvant chemotherapy on breast cancer outcomes.Pariser A, Mougalian S, Sedghi T, Gross C, Killelea B. Treatment effect of neoadjuvant endocrine therapy compared to neoadjuvant chemotherapy on breast cancer outcomes. Journal Of Clinical Oncology 2018, 36: e12630-e12630. DOI: 10.1200/jco.2018.36.15_suppl.e12630.
  • Adherence to Guidelines for Breast Surveillance in Breast Cancer Survivors.Ruddy KJ, Sangaralingham L, Freedman RA, Mougalian S, Neuman H, Greenberg C, Jemal A, Duma N, Haddad TC, Lemaine V, Ghosh K, Hieken TJ, Hunt K, Vachon C, Gross C, Shah ND. Adherence to Guidelines for Breast Surveillance in Breast Cancer Survivors. Journal Of The National Comprehensive Cancer Network 2018, 16: 526-534. PMID: 29752327, DOI: 10.6004/jnccn.2018.7001.
  • Risk of Occult Uterine Cancer in MyomectomyDesai V, Wright J, Gross C, Lin H, Schwartz P, Xu X. Risk of Occult Uterine Cancer in Myomectomy Obstetrics And Gynecology 2018, 131: 41s. DOI: 10.1097/01.aog.0000532981.09677.4b.
  • Occult Uterine Cancer in Presumed Benign HysterectomiesXu X, Wright J, Gross C, Lin H, Schwartz P, Desai V. Occult Uterine Cancer in Presumed Benign Hysterectomies Obstetrics And Gynecology 2018, 131: 42s-43s. DOI: 10.1097/01.aog.0000532985.32547.8b.
  • MP44-16 VARIATION IN NATIONAL OPIOID PRESCRIBING PATTERNS FOLLOWING SURGERY FOR KIDNEY STONESLeapman M, DeRycke E, Skanderson M, Becker W, Makarov D, Gross C, Driscoll M, Motamedinia P, Bathulapalli H, Mattocks K, Brandt C, Haskell S, Bastian L. MP44-16 VARIATION IN NATIONAL OPIOID PRESCRIBING PATTERNS FOLLOWING SURGERY FOR KIDNEY STONES Investigative Urology 2018, 199: e594. DOI: 10.1016/j.juro.2018.02.1435.
  • MP53-08 USE OF PROSTATE MAGNETIC RESONANCE IMAGING AMONG MEDICARE BENEFICIARIES WITH LOW-RISK PROSTATE CANCER IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEFINITIVE TREATMENTLeapman M, Wang R, Park H, Yu J, Gross C, Ma X. MP53-08 USE OF PROSTATE MAGNETIC RESONANCE IMAGING AMONG MEDICARE BENEFICIARIES WITH LOW-RISK PROSTATE CANCER IS ASSOCIATED WITH A HIGHER LIKELIHOOD OF DEFINITIVE TREATMENT Investigative Urology 2018, 199: e707. DOI: 10.1016/j.juro.2018.02.1679.
  • MP12-15 NATIONAL TRENDS IN THE MANAGEMENT OF LOCALIZED PROSTATE CANCER FROM A POPULATION-BASED COHORT OF PRIVATELY INSURED PATIENTSKim S, Karnes J, Bukavina L, Van Houten H, Gross C, Mwangi R, Shah N. MP12-15 NATIONAL TRENDS IN THE MANAGEMENT OF LOCALIZED PROSTATE CANCER FROM A POPULATION-BASED COHORT OF PRIVATELY INSURED PATIENTS Investigative Urology 2018, 199: e141-e142. DOI: 10.1016/j.juro.2018.02.402.
  • 128 The care and outcomes of older persons with lung cancer in England and US, 2008–2012Andreano A, Peake M, Valsecchi M, Janes S, Pritchard-Jones K, Hoag J, Gross C. 128 The care and outcomes of older persons with lung cancer in England and US, 2008–2012 Lung Cancer 2018, 115: s54-s55. DOI: 10.1016/s0169-5002(18)30154-5.
  • Stereotactic Body Radiation Therapy for Oligometastatic Disease: A Multi-Institutional Retrospective Survival AnalysisBui D, Magnuson W, Lester-Coll N, Qian J, Ross R, Soulos P, Shafman T, Dosoretz A, Evans S, Yu J, Gross C, Decker R. Stereotactic Body Radiation Therapy for Oligometastatic Disease: A Multi-Institutional Retrospective Survival Analysis International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e443. DOI: 10.1016/j.ijrobp.2017.06.1664.
  • Use of Alternative Medicine for Cancer and Its Impact on SurvivalJohnson S, Park H, Gross C, Yu J. Use of Alternative Medicine for Cancer and Its Impact on Survival International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e401. DOI: 10.1016/j.ijrobp.2017.06.1562.
  • Use of Alternative Medicine for Cancer and Its Impact on Survival.Johnson SB, Park HS, Gross CP, Yu JB. Use of Alternative Medicine for Cancer and Its Impact on Survival. Journal Of The National Cancer Institute 2017, 110: 121-124. PMID: 28922780, DOI: 10.1093/jnci/djx145.
  • Concurrent Care and Aggressive End-of-Life Lung Cancer CarePresley C, Han L, O'leary J, Chao H, Shamas T, Kerin A, Rose M, Gross C. Concurrent Care and Aggressive End-of-Life Lung Cancer Care Journal Of Thoracic Oncology 2017, 12: s1545. DOI: 10.1016/j.jtho.2017.06.058.
  • Racial disparities in the use of programmed death-1 checkpoint inhibitors.O'Connor J, Seidl-Rathkopf K, Torres A, You P, Nussbaum N, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Racial disparities in the use of programmed death-1 checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: 3068-3068. DOI: 10.1200/jco.2017.35.15_suppl.3068.
  • Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer.Presley C, Soulos P, Chiang A, Longtine J, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy A, Agarwala V, Gross C. Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. Journal Of Clinical Oncology 2017, 35: 6563-6563. DOI: 10.1200/jco.2017.35.15_suppl.6563.
  • Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors.O'Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres A, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy A, Gross C. Adoption of immunotherapy into real-world practice: Insights from the use of checkpoint inhibitors. Journal Of Clinical Oncology 2017, 35: e14583-e14583. DOI: 10.1200/jco.2017.35.15_suppl.e14583.
  • Functional trajectories before and after a new cancer diagnosis among community-living older adults.Presley C, Hurria A, Han L, Leo-Summers L, Gross C, Allore H, Davidoff A, Gill T. Functional trajectories before and after a new cancer diagnosis among community-living older adults. Journal Of Clinical Oncology 2017, 35: e21547-e21547. DOI: 10.1200/jco.2017.35.15_suppl.e21547.
  • Duration of neoadjuvant endocrine therapy and breast cancer outcomes.Mougalian S, Soulos P, Lannin D, Pusztai L, Gross C, Killelea B. Duration of neoadjuvant endocrine therapy and breast cancer outcomes. Journal Of Clinical Oncology 2017, 35: e12129-e12129. DOI: 10.1200/jco.2017.35.15_suppl.e12129.
  • Physician volume and discontinuation of rituximab during lymphoma treatment.Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.
  • Use of alternative medicine for cancer and its impact on survival.Johnson S, Gross C, Park H, Yu J. Use of alternative medicine for cancer and its impact on survival. Journal Of Clinical Oncology 2017, 35: e18175-e18175. DOI: 10.1200/jco.2017.35.15_suppl.e18175.
  • Mammography use in breast cancer survivors: An administrative claims study.Ruddy K, Sangaralingham L, Neuman H, Greenberg C, Freedman R, Jemal A, Mougalian S, Hunt K, Haddad T, Lemaine V, Ghosh K, Hieken T, Vachon C, Gross C, Shah N. Mammography use in breast cancer survivors: An administrative claims study. Journal Of Clinical Oncology 2017, 35: 6531-6531. DOI: 10.1200/jco.2017.35.15_suppl.6531.
  • Impact of hearing and visual impairment in older adults with cancer.Soto Perez De Celis E, Sun C, Tew W, Mohile S, Gajra A, Klepin H, Owusu C, Gross C, Muss H, Lichtman S, Chapman A, Cohen H, Dale W, Kim H, Katheria V, Hurria A. Impact of hearing and visual impairment in older adults with cancer. Journal Of Clinical Oncology 2017, 35: 10036-10036. DOI: 10.1200/jco.2017.35.15_suppl.10036.
  • Risk factors for hospitalizations (HOS) among older adults with gastrointestinal (GI) cancers receiving chemotherapy.Li D, Sun C, Levi A, Klepin H, Elias R, Mohile S, Tew W, Lim D, Chung V, Chao J, Owusu C, Muss H, Lichtman S, Gross C, Chapman A, Gajra A, Cohen H, Katheria V, Hurria A. Risk factors for hospitalizations (HOS) among older adults with gastrointestinal (GI) cancers receiving chemotherapy. Journal Of Clinical Oncology 2017, 35: e21523-e21523. DOI: 10.1200/jco.2017.35.15_suppl.e21523.
  • MP69-07 HASHTAG PEER-REVIEW: DOES EARLY SOCIAL MEDIA SUCCESS CORRELATE WITH CONVENTIONAL METRICS OF PUBLICATION IMPACT?Nguyen K, Gross C, Cooperberg M, Katz M, Hittelman A, Syed J, Schulam P, Leapman M. MP69-07 HASHTAG PEER-REVIEW: DOES EARLY SOCIAL MEDIA SUCCESS CORRELATE WITH CONVENTIONAL METRICS OF PUBLICATION IMPACT? Investigative Urology 2017, 197: e928-e929. DOI: 10.1016/j.juro.2017.02.2303.
  • PD09-02 RACIAL VARIATION IN THE REFUSAL OF INITIAL TREATMENT PLAN AMONG MEN DIAGNOSED WITH LOCALIZED PROSTATE CANCERScarberry K, Scarberry K, Abouassaly R, Gonzalez C, Gross C, Shah N, Meropol N, Psutka S, Prasad S, Bukavina L, Kim S. PD09-02 RACIAL VARIATION IN THE REFUSAL OF INITIAL TREATMENT PLAN AMONG MEN DIAGNOSED WITH LOCALIZED PROSTATE CANCER Investigative Urology 2017, 197: e194. DOI: 10.1016/j.juro.2017.02.552.
  • The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast CancerPollack CE, Soulos PR, Herrin J, Xu X, Christakis NA, Forman HP, Yu JB, Killelea BK, Wang SY, Gross CP. The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer Journal Of The National Cancer Institute 2017, 109 PMID: 28376191, PMCID: PMC6059114, DOI: 10.1093/jnci/djw330.
  • Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study. Journal Of The National Comprehensive Cancer Network 2017, 15: 346-354. PMID: 28275035, DOI: 10.6004/jnccn.2017.0034.
  • Abstract P3-10-03: Socioeconomic disparities in needle biopsy prior to breast cancer surgery across physician referral networksKillelea B, Herrin J, Soulos P, Pollack C, Forman H, Yu J, Xu X, Tannenbaum S, Wang S, Gross C. Abstract P3-10-03: Socioeconomic disparities in needle biopsy prior to breast cancer surgery across physician referral networks Cancer Research 2017, 77: p3-10-03-p3-10-03. DOI: 10.1158/1538-7445.sabcs16-p3-10-03.
  • Primary care physician continuity and end-of-life care intensity among Medicare cancer decedents.Wang S, Cramer L, Pollack C, Gross C. Primary care physician continuity and end-of-life care intensity among Medicare cancer decedents. Journal Of Clinical Oncology 2017, 35: 38-38. DOI: 10.1200/jco.2017.35.5_suppl.38.
  • Examining Trends in the CMS Medicare Provider Utilization and Payment Database for Radiation OncologistsJairam V, Gross C, Yu J. Examining Trends in the CMS Medicare Provider Utilization and Payment Database for Radiation Oncologists International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e404-e405. DOI: 10.1016/j.ijrobp.2016.06.1646.
  • A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation TherapyStahl J, Ross R, Harder E, Mancini B, Soulos P, Dosoretz A, Finkelstein S, Shafman T, Husain Z, Evans S, Yu J, Gross C, Decker R. A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s174-s175. DOI: 10.1016/j.ijrobp.2016.06.438.
  • Modern Radiation Therapy for Left-Sided Breast Cancer: An Analysis of Mean Heart Dose Within Diverse Practice SettingsHong J, Gross C, Shafman T, Hu X, Yu J, Ross R, Dosoretz A, Park H, Finkelstein S, Soulos P, Evans S. Modern Radiation Therapy for Left-Sided Breast Cancer: An Analysis of Mean Heart Dose Within Diverse Practice Settings International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s209. DOI: 10.1016/j.ijrobp.2016.06.520.
  • Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy Versus Moderate Hypofractionation for Clinically Localized Prostate CancerJohnson S, Soulos P, Shafman T, Mantz C, Dosoretz A, Ross R, Finkelstein S, Collins S, Suy S, Brower J, Ritter M, King C, Kupelian P, Horwitz E, Pollack A, Abramowitz M, Hallman M, Faria S, Gross C, Yu J. Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy Versus Moderate Hypofractionation for Clinically Localized Prostate Cancer International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e242. DOI: 10.1016/j.ijrobp.2016.06.1232.
  • Variation in Private Payer Payments to Cancer SurgeonsBongiovanni T, Kim S, Gross C, Kim A, Killelea B. Variation in Private Payer Payments to Cancer Surgeons Journal Of The American College Of Surgeons 2016, 223: s121-s122. DOI: 10.1016/j.jamcollsurg.2016.06.252.
  • Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapyWang E, Wang S, Soulos P, Chen R, Kim S, Gross C, Yu J. Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy Journal Of Radiation Oncology 2016, 6: 295-300. DOI: 10.1007/s13566-016-0269-0.
  • Impact of weight loss and exercise on VEGF levels in breast cancer survivors.Sanft T, Cartmel B, Harrigan M, Li F, Loftfield E, Playdon M, Zhou Y, Gross C, Ligibel J, SCHMITZ K, Hershman D, Pusztai L, Irwin M. Impact of weight loss and exercise on VEGF levels in breast cancer survivors. Journal Of Clinical Oncology 2016, 34: 10103-10103. DOI: 10.1200/jco.2016.34.15_suppl.10103.
  • Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study.Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. DOI: 10.1200/jco.2016.34.15_suppl.e18136.
  • The impact of social contagion on physician adoption of breast cancer imaging.Pollack C, Soulos P, Herrin J, Xu X, Christakis N, Forman H, Yu J, Killelea B, Wang S, Gross C. The impact of social contagion on physician adoption of breast cancer imaging. Journal Of Clinical Oncology 2016, 34: 6534-6534. DOI: 10.1200/jco.2016.34.15_suppl.6534.
  • Association of length of hospice enrollment with regional variation in end-of-life care expenditures.Wang S, Huang S, Hsu S, Gross C. Association of length of hospice enrollment with regional variation in end-of-life care expenditures. Journal Of Clinical Oncology 2016, 34: 10030-10030. DOI: 10.1200/jco.2016.34.15_suppl.10030.
  • Associations of pre- and post-cancer depression with end-of-life cancer care intensity.Doan K, Levy B, Gross C, Wang S. Associations of pre- and post-cancer depression with end-of-life cancer care intensity. Journal Of Clinical Oncology 2016, 34: 10031-10031. DOI: 10.1200/jco.2016.34.15_suppl.10031.
  • The benefit of modern cancer therapy for older patients.Mahal A, Cramer L, Wang E, Wang S, Davidoff A, Gross C, Yu J. The benefit of modern cancer therapy for older patients. Journal Of Clinical Oncology 2016, 34: e18141-e18141. DOI: 10.1200/jco.2016.34.15_suppl.e18141.
  • Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort.Presley C, Harrington E, Gippetti J, Agarwala V, Bowser B, Adelson K, Herbst R, Abernethy A, Gross C. Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort. Journal Of Clinical Oncology 2016, 34: e20621-e20621. DOI: 10.1200/jco.2016.34.15_suppl.e20621.
  • Bone density screening in postmenopausal women with early-stage breast cancer on aromatase inhibitors.Stratton J, Hu X, Soulos P, Davidoff A, Pusztai L, Gross C, Mougalian S. Bone density screening in postmenopausal women with early-stage breast cancer on aromatase inhibitors. Journal Of Clinical Oncology 2016, 34: 6599-6599. DOI: 10.1200/jco.2016.34.15_suppl.6599.
  • Randomized trial assessing the impact of survivorship care plans on the quality of care for childhood cancer survivors.Gross C, Ross W, Rotatori J, Mitchell H, Ma X, Kadan-Lottick N. Randomized trial assessing the impact of survivorship care plans on the quality of care for childhood cancer survivors. Journal Of Clinical Oncology 2016, 34: 10007-10007. DOI: 10.1200/jco.2016.34.15_suppl.10007.
  • Acute care use among women receiving adjuvant chemotherapy for breast cancer.Ruddy K, Sangaralingham L, Freedman R, Jemal A, Thompson C, Hashmi S, Mougalian S, Gross C, Shah N. Acute care use among women receiving adjuvant chemotherapy for breast cancer. Journal Of Clinical Oncology 2016, 34: 6543-6543. DOI: 10.1200/jco.2016.34.15_suppl.6543.
  • Complex association between social support and chemotherapy-related toxicities in older cancer patients.Shahrokni A, Sun C, Tew W, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Gajra A, Katheria V, Cohen H, Hurria A. Complex association between social support and chemotherapy-related toxicities in older cancer patients. Journal Of Clinical Oncology 2016, 34: 10036-10036. DOI: 10.1200/jco.2016.34.15_suppl.10036.
  • Predictors of unplanned hospitalizations among older adults receiving cancer chemotherapy.Klepin H, Sun C, Smith D, Elias R, Trevino K, Bryant A, Nelson C, Tew W, Mohile S, Owusu C, Gross C, Gajra A, Lichtman S, Katheria V, Hurria A. Predictors of unplanned hospitalizations among older adults receiving cancer chemotherapy. Journal Of Clinical Oncology 2016, 34: 10057-10057. DOI: 10.1200/jco.2016.34.15_suppl.10057.
  • Randomized Trial Of Exercise On Body Composition In Breast Cancer Survivors Taking Aromatase InhibitorsThomas G, Cartmel B, Harrigan M, Fiellin M, Capozza S, Zhou Y, Ercolano E, Gross C, Hershman D, Ligibel J, Schmitz K, Li F, Sanft T, Irwin M. Randomized Trial Of Exercise On Body Composition In Breast Cancer Survivors Taking Aromatase Inhibitors Medicine & Science In Sports & Exercise 2016, 48: 334. DOI: 10.1249/01.mss.0000486010.57056.60.
  • Abstract P3-13-01: Impact of routine cavity shave margins on time and money: Results from the SHAVE trialChagpar A, Longley P, Horowitz N, Killelea B, Tsangaris T, Li F, Butler M, Stavris K, Yao X, Harigopal M, Bossuyt V, Lannin D, Pusztai L, Loftus M, Davidoff A, Gross C. Abstract P3-13-01: Impact of routine cavity shave margins on time and money: Results from the SHAVE trial Cancer Research 2016, 76: p3-13-01-p3-13-01. DOI: 10.1158/1538-7445.sabcs15-p3-13-01.
  • Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot studyEpstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Pusztai L, Gross C, Mougalian S. Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study Cancer Research 2016, 76: p5-11-03-p5-11-03. DOI: 10.1158/1538-7445.sabcs15-p5-11-03.
  • Abstract P6-11-03: A cost effectiveness analysis of baseline left ventricular function assessment for breast cancer patients undergoing anthracycline chemotherapySafonov A, Hatzis C, Stratton J, Gross C, Russell R, Pusztai L, Abu-Khalaf M. Abstract P6-11-03: A cost effectiveness analysis of baseline left ventricular function assessment for breast cancer patients undergoing anthracycline chemotherapy Cancer Research 2016, 76: p6-11-03-p6-11-03. DOI: 10.1158/1538-7445.sabcs15-p6-11-03.
  • Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Blood 2015, 126: 3285-3285. DOI: 10.1182/blood.v126.23.3285.3285.
  • Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)Zeidan A, Wang R, Davidoff A, Gore S, Soulos P, Huntington S, Gross C, Ma X. Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US) Blood 2015, 126: 873-873. DOI: 10.1182/blood.v126.23.873.873.
  • Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based StudyWang R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study Blood 2015, 126: 3295-3295. DOI: 10.1182/blood.v126.23.3295.3295.
  • Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based StudyZeidan A, Long J, Wang R, Yu J, Hall J, Abel G, Gore S, Gross C, Ma X, Davidoff A. Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study Blood 2015, 126: 1676-1676. DOI: 10.1182/blood.v126.23.1676.1676.
  • Higher Facility Case Volume of Stereotactic Body Radiation Therapy Is Associated With Improved Overall Survival in Clinical Stage I Non-Small Cell Lung CancerPark H, Wang E, Corso C, Rutter C, Wilson L, Kim A, Gross C, Yu J, Decker R. Higher Facility Case Volume of Stereotactic Body Radiation Therapy Is Associated With Improved Overall Survival in Clinical Stage I Non-Small Cell Lung Cancer International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s186-s187. DOI: 10.1016/j.ijrobp.2015.07.447.
  • Trends in Hospital Owned Practices Within Radiation OncologyAneja S, Smith B, Gross C, Haffty B, Wilson L, Yu J. Trends in Hospital Owned Practices Within Radiation Oncology International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e371-e372. DOI: 10.1016/j.ijrobp.2015.07.1495.
  • Evaluation at Academic Centers Increases the Likelihood of Active Surveillance in Low-Risk Prostate CancerLester-Coll N, Park H, Rutter C, Corso C, Mancini B, Yeboa D, Kim S, Gross C, Yu J. Evaluation at Academic Centers Increases the Likelihood of Active Surveillance in Low-Risk Prostate Cancer International Journal Of Radiation Oncology • Biology • Physics 2015, 93: s118. DOI: 10.1016/j.ijrobp.2015.07.281.
  • Stereotactic Body Radiation Therapy for Prostate Cancer: Adoption in the United States From 2005 to 2012Bledsoe T, Rutter C, Corso C, Aneja S, Lester-Coll N, Wang E, Potosky A, Gross C, Yu J, Park H. Stereotactic Body Radiation Therapy for Prostate Cancer: Adoption in the United States From 2005 to 2012 International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e359. DOI: 10.1016/j.ijrobp.2015.07.1462.
  • Genomic Predictors of Biochemical Failure Following Radical ProstatectomyAneja S, Gross C, Glazer P, Yu J. Genomic Predictors of Biochemical Failure Following Radical Prostatectomy International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e251-e252. DOI: 10.1016/j.ijrobp.2015.07.1180.
  • The Relationship Between Geographic Access to Plastic Surgeons and Immediate Breast Reconstruction Rates Among Women Undergoing Mastectomy for CancerFox J, Bauder A, Gross C, Killelea B, Butler P, Kovach S. The Relationship Between Geographic Access to Plastic Surgeons and Immediate Breast Reconstruction Rates Among Women Undergoing Mastectomy for Cancer Plastic & Reconstructive Surgery 2015, 136: 91-92. DOI: 10.1097/01.prs.0000472391.73232.70.
  • Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes (MDS)Zeidan A, Wang R, Davidoff A, Gore S, Gross C, Ma X. Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes (MDS) Clinical Lymphoma Myeloma & Leukemia 2015, 15: s44-s45. DOI: 10.1016/j.clml.2015.07.094.
  • Changes in prostate cancer presentation for radiation oncology care after USPSTF recommendations, 2007-2013.Su K, Yu J, Shafman T, Evans S, Decker R, Dosoretz A, Dosoretz D, Ross R, Salenius S, Finkelstein S, Hall J, Soulos P, Gross C. Changes in prostate cancer presentation for radiation oncology care after USPSTF recommendations, 2007-2013. Journal Of Clinical Oncology 2015, 33: e16070-e16070. DOI: 10.1200/jco.2015.33.15_suppl.e16070.
  • Trends and regional variation of end-of-life cancer care in the Medicare program.Wang S, Hall J, Long J, Pollack C, Bradley E, Adelson K, Gross C. Trends and regional variation of end-of-life cancer care in the Medicare program. Journal Of Clinical Oncology 2015, 33: 9526-9526. DOI: 10.1200/jco.2015.33.15_suppl.9526.
  • Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer.Mougalian S, Long J, Hall J, Adelson K, Abu-Khalaf M, Pusztai L, Gross C. Outcomes of adjuvant ACT vs. TC chemotherapy in older women with breast cancer. Journal Of Clinical Oncology 2015, 33: 1009-1009. DOI: 10.1200/jco.2015.33.15_suppl.1009.
  • Contemporary national trends of prostate cancer screening among privately insured patients in the United States.Kim S, Karnes J, Gross C, Meropol N, Van Houten H, Abouassaly R, Shah N. Contemporary national trends of prostate cancer screening among privately insured patients in the United States. Journal Of Clinical Oncology 2015, 33: 5065-5065. DOI: 10.1200/jco.2015.33.15_suppl.5065.
  • Variation in surgeon payment for cancer resection.Bongiovanni T, Kim A, Killelea B, Kim S, Gross C. Variation in surgeon payment for cancer resection. Journal Of Clinical Oncology 2015, 33: e17802-e17802. DOI: 10.1200/jco.2015.33.15_suppl.e17802.
  • “The burden upon me”: The complexity of healthcare utilization among Medicare patients undergoing curative lung cancer treatment.Presley C, Soulos P, Yu J, Gross C. “The burden upon me”: The complexity of healthcare utilization among Medicare patients undergoing curative lung cancer treatment. Journal Of Clinical Oncology 2015, 33: 7533-7533. DOI: 10.1200/jco.2015.33.15_suppl.7533.
  • Association between renal function and chemotherapy-related toxicity in older adults with cancer.Peterson L, Hurria A, Feng T, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Gajra A, Glezerman I, Katheria V, Zavala L, Smith D, Tew W. Association between renal function and chemotherapy-related toxicity in older adults with cancer. Journal Of Clinical Oncology 2015, 33: 9509-9509. DOI: 10.1200/jco.2015.33.15_suppl.9509.
  • Association of geriatric assessment factors with falls in older adults initiating chemotherapy.Wildes T, Tew W, Maggiore R, Edwards B, Cohen H, Smith D, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Gajra A, Katheria V, Akiba C, Hurria A. Association of geriatric assessment factors with falls in older adults initiating chemotherapy. Journal Of Clinical Oncology 2015, 33: 9542-9542. DOI: 10.1200/jco.2015.33.15_suppl.9542.
  • Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely CampaignMakarov DV, Soulos PR, Gold HT, Yu JB, Sen S, Ross JS, Gross CP. Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign JAMA Oncology 2015, 1: 185-194. PMID: 26181021, PMCID: PMC4707944, DOI: 10.1001/jamaoncol.2015.37.
  • Abstract P1-15-04: The adoption of hypofractionated whole breast irradiation for early-stage breast cancer: A national cancer data base analysisWang E, Mougalian S, Soulos P, Rutter C, Evans S, Haffty B, Gross C, Yu J. Abstract P1-15-04: The adoption of hypofractionated whole breast irradiation for early-stage breast cancer: A national cancer data base analysis 2015, p1-15-04-p1-15-04. DOI: 10.1158/1538-7445.sabcs14-p1-15-04.
  • MP44-10 TREATMENT TRENDS OF SMALL RENAL MASSES IN PATIENTS OF ADVANCED AGEDong S, Kiechle J, Kim S, Abouassaly R, Cherullo E, Ponsky L, Gross C, Shah N, Zhu H. MP44-10 TREATMENT TRENDS OF SMALL RENAL MASSES IN PATIENTS OF ADVANCED AGE Investigative Urology 2015, 193: e530. DOI: 10.1016/j.juro.2015.02.1552.
  • MP84-05 VARIATION IN SURGICAL MARGIN STATUS BY SURGICAL APPROACH AMONG PATIENTS UNDERGOING PARTIAL NEPHRECTOMY FOR SMALL RENAL MASSESKiechle J, Abouassaly R, Tabayoyong W, Dong S, Smaldone M, Cherullo E, Gross C, Shah N, Zhu H, Kim S. MP84-05 VARIATION IN SURGICAL MARGIN STATUS BY SURGICAL APPROACH AMONG PATIENTS UNDERGOING PARTIAL NEPHRECTOMY FOR SMALL RENAL MASSES Investigative Urology 2015, 193: e1059. DOI: 10.1016/j.juro.2015.02.1972.
  • PD44-05 CONTEMPORARY NATIONAL TRENDS OF PROSTATE CANCER SCREENING AMONG PRIVATELY INSURED PATIENTS IN THE UNITED STATESKim S, Karnes R, Gross C, Van Houten H, Abouassaly R, Shah N. PD44-05 CONTEMPORARY NATIONAL TRENDS OF PROSTATE CANCER SCREENING AMONG PRIVATELY INSURED PATIENTS IN THE UNITED STATES Investigative Urology 2015, 193: e899. DOI: 10.1016/j.juro.2015.02.2551.
  • MP69-08 SYSTEMATIC REVIEW AND META-ANALYSIS OF TARGETED THERAPY FOR OVERALL SURVIVAL, COMPLETE RESPONSE AND QUALITY OF LIFE FOR METASTATIC RENAL CELL CARCINOMAHan Y, Wietsma A, Gross C, Shah N, Abouassaly R, Smaldone M, Boorjian S, Hoimes C, Cooney M, Kim S. MP69-08 SYSTEMATIC REVIEW AND META-ANALYSIS OF TARGETED THERAPY FOR OVERALL SURVIVAL, COMPLETE RESPONSE AND QUALITY OF LIFE FOR METASTATIC RENAL CELL CARCINOMA Investigative Urology 2015, 193: e869-e870. DOI: 10.1016/j.juro.2015.02.2512.
  • 80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDYWane R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. 80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY Leukemia Research 2015, 39: s39. DOI: 10.1016/s0145-2126(15)30081-3.
  • MP9-03 THE EFFECT OF HEALTHCARE SYSTEM ON APPROPRIATENESS OF PROSTATE CANCER IMAGING: DO PATIENTS GET BETTER CARE IN VA OR FEE-FOR-SERVICE MEDICARE?Makarov D, Gold H, Walter D, Eugenio E, Sherman S, Gross C, Zeliadt S. MP9-03 THE EFFECT OF HEALTHCARE SYSTEM ON APPROPRIATENESS OF PROSTATE CANCER IMAGING: DO PATIENTS GET BETTER CARE IN VA OR FEE-FOR-SERVICE MEDICARE? Investigative Urology 2015, 193: e102-e103. DOI: 10.1016/j.juro.2015.02.363.
  • MP56-06 ASSOCIATION BETWEEN PROVIDER-LEVEL FACTORS AND LYMPH NODE DISSECTION OUTCOMES DURING RADICAL PROSTATECTOMY: A NATIONAL CANCER DATABASE ANALYSISKiechle J, Wang E, Yu J, Gross C, Abouassaly R, Cherullo E, Smaldone M, Shah N, Trinh Q, Sun M, Kim S. MP56-06 ASSOCIATION BETWEEN PROVIDER-LEVEL FACTORS AND LYMPH NODE DISSECTION OUTCOMES DURING RADICAL PROSTATECTOMY: A NATIONAL CANCER DATABASE ANALYSIS Investigative Urology 2015, 193: e683. DOI: 10.1016/j.juro.2015.02.2070.
  • Association between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis.Kiechle J, Wang E, Yu J, Gross C, Abouassaly R, Cherullo E, Smaldone M, Shah N, Trinh Q, Sun M, Kim S. Association between provider-level factors and lymph node dissection outcomes during radical prostatectomy: A national cancer database analysis. Journal Of Clinical Oncology 2015, 33: 89-89. DOI: 10.1200/jco.2015.33.7_suppl.89.
  • Surveillance Practice Patterns After Curative Intent Therapy for Stage I Non-small Cell Lung Cancer in the Medicare PopulationErb C, Soulos P, Tanoue L, Gross C. Surveillance Practice Patterns After Curative Intent Therapy for Stage I Non-small Cell Lung Cancer in the Medicare Population CHEST Journal 2014, 146: 607a. DOI: 10.1378/chest.1992085.
  • Assessing the validity of the CARG (Cancer and Aging Research Group) chemotherapy toxicity score for reduced modelsGajra A, Feng T, CARG, Mohile S, Owusu C, Klepin H, Gross C, Katheria V, Tew W, Hurria A, Group C. Assessing the validity of the CARG (Cancer and Aging Research Group) chemotherapy toxicity score for reduced models Journal Of Geriatric Oncology 2014, 5: s64. DOI: 10.1016/j.jgo.2014.09.116.
  • Comparative Effectiveness of Stereotactic Body Radiation Therapy Versus Surgery for Stage I Non-small Cell Lung CancerYu J, Soulos P, Cramer L, Decker R, Kim A, Gross C. Comparative Effectiveness of Stereotactic Body Radiation Therapy Versus Surgery for Stage I Non-small Cell Lung Cancer International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s138. DOI: 10.1016/j.ijrobp.2014.05.596.
  • PS1-44: Time to Surgery for MelanomaLott J, Soulos P, Aminawung J, Gross C. PS1-44: Time to Surgery for Melanoma Clinical Medicine & Research 2014, 12: 78-78. PMCID: PMC4453318, DOI: 10.3121/cmr.2014.1250.ps1-44.
  • Impact of 3 Decades of Screening on Racial Disparities in Cervical Cancer IncidenceYang D, Pamela S, Brigette D, Gross C, Yu J. Impact of 3 Decades of Screening on Racial Disparities in Cervical Cancer Incidence International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s579-s580. DOI: 10.1016/j.ijrobp.2014.05.1745.
  • Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic ImplicationsKillelea BK, Long JB, Chagpar AB, Ma X, Wang R, Ross JS, Gross CP. Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications Journal Of The National Cancer Institute 2014, 106 PMID: 25031307, PMCID: PMC4155428, DOI: 10.1093/jnci/dju159.
  • Abstract 107: Cardiovascular Events, Early Discontinuation of Trastuzumab, and Their Impact on SurvivalChen J, Wang S, Long J, Hurria A, Owusu C, Steingart R, Gross C. Abstract 107: Cardiovascular Events, Early Discontinuation of Trastuzumab, and Their Impact on Survival Circulation Cardiovascular Quality And Outcomes 2014, 7 DOI: 10.1161/circoutcomes.7.suppl_1.107.
  • Abstract 139: A Novel Taxonomy for Acute Myocardial Infarction in Young WomenSpatz E, Curry L, Gross C, Masoudi F, Dryer R, Bueno H, Lampropulos J, Chaudhry S, Zhou S, D'Onofrio G, Spertus J, Safdar B, Lansky A, Krumholz H. Abstract 139: A Novel Taxonomy for Acute Myocardial Infarction in Young Women Circulation Cardiovascular Quality And Outcomes 2014, 7 DOI: 10.1161/circoutcomes.7.suppl_1.139.
  • Abstract 280: Cardiologist Consultation and Associated Outcomes for Older Women with Heart Failure after Breast Cancer TherapyChen J, Long J, Chen C, Wang S, Steingart R, Gross C. Abstract 280: Cardiologist Consultation and Associated Outcomes for Older Women with Heart Failure after Breast Cancer Therapy Circulation Cardiovascular Quality And Outcomes 2014, 7 DOI: 10.1161/circoutcomes.7.suppl_1.280.
  • Effect of exercise on weight, body fat, and serum inflammatory biomarkers in breast cancer survivors with aromatase inhibitor arthralgias: The hormones and physical exercise (HOPE) study.Irwin M, Cartmel B, Gross C, Li F, Yao X, Yao X, Fiellin M, Fiellin M, Ercolano E, Ercolano E, Harrigan M, Zhou Y, Zhou Y, Sanft T, Schmitz K, Schmitz K, Hershman D, Hershman D, Ligibel J, Ligibel J. Effect of exercise on weight, body fat, and serum inflammatory biomarkers in breast cancer survivors with aromatase inhibitor arthralgias: The hormones and physical exercise (HOPE) study. Journal Of Clinical Oncology 2014, 32: 9536-9536. DOI: 10.1200/jco.2014.32.15_suppl.9536.
  • Diffusion of stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) in the Medicare population, 2007-2009.Yu J, Soulos P, Cramer L, Decker R, Kim A, Gross C. Diffusion of stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) in the Medicare population, 2007-2009. Journal Of Clinical Oncology 2014, 32: 7575-7575. DOI: 10.1200/jco.2014.32.15_suppl.7575.
  • Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer.Han L, Shah N, Gross C, Ross J, Nguyen P, Smaldone M, Tilburt J, Yu J, Trinh Q, Karnes R, Ranasinghe W, Sun M, Kim S. Perceptions of radiation oncologists and urologists about new technology for the treatment of prostate cancer. Journal Of Clinical Oncology 2014, 32: e16085-e16085. DOI: 10.1200/jco.2014.32.15_suppl.e16085.
  • Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment.Graham-Steed T, Soulos P, Dearing N, Concato J, Tinetti M, Gross C. Development and validation of a prognostic index for fracture risk in older men undergoing prostate cancer treatment. Journal Of Clinical Oncology 2014, 32: 5056-5056. DOI: 10.1200/jco.2014.32.15_suppl.5056.
  • Estimating the impact of screening on three decades of cervical cancer incidence.Yang D, Soulos P, Davis B, Gross C, Yu J. Estimating the impact of screening on three decades of cervical cancer incidence. Journal Of Clinical Oncology 2014, 32: 1518-1518. DOI: 10.1200/jco.2014.32.15_suppl.1518.
  • Out-of-pockets costs for patients receiving targeted agents for metastatic renal cell carcinoma.Kim S, Gross C, Abouassaly R, Psutka S, Van Houten H, Thompson R, Smaldone M, Trinh Q, Sun M, Han L, Shah N. Out-of-pockets costs for patients receiving targeted agents for metastatic renal cell carcinoma. Journal Of Clinical Oncology 2014, 32: e15598-e15598. DOI: 10.1200/jco.2014.32.15_suppl.e15598.
  • Erratum: Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancerKim S, Gross C, Nguyen P, Smaldone M, Thompson R, Shah N, Kutikov A, Han L, Karnes R, Ziegenfuss J, Tilburt J. Erratum: Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer Prostate Cancer And Prostatic Diseases 2014, 17: 212-212. DOI: 10.1038/pcan.2014.14.
  • MP11-06 REGIONAL-LEVEL INAPPROPRIATE IMAGING RATES FOR PROSTATE AND BREAST CANCERS ARE CORRELATED: POTENTIAL LESSONS FOR THE CHOOSING WISELY CAMPAIGNMakarov D, Sen S, Soulos P, Gold H, Yu J, Ross J, Gross C. MP11-06 REGIONAL-LEVEL INAPPROPRIATE IMAGING RATES FOR PROSTATE AND BREAST CANCERS ARE CORRELATED: POTENTIAL LESSONS FOR THE CHOOSING WISELY CAMPAIGN Investigative Urology 2014, 191: e97. DOI: 10.1016/j.juro.2014.02.421.
  • MP6-06 POPULATION-LEVEL TRENDS IN THE ADOPTION OF NOVEL TARGETED AGENTS FOR SYSTEMIC THERAPY AND IMPACT ON RATES OF CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMAPsutka S, Kim S, Gross C, Van Houten H, Thompson R, Abouassaly R, Weight C, Leibovich B, Shah N. MP6-06 POPULATION-LEVEL TRENDS IN THE ADOPTION OF NOVEL TARGETED AGENTS FOR SYSTEMIC THERAPY AND IMPACT ON RATES OF CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA Investigative Urology 2014, 191: e58. DOI: 10.1016/j.juro.2014.02.240.
  • PD17-08 THE EFFECT OF THE SURGICAL ROBOT ON THE HOSPITAL-LEVEL UTILIZATION OF PARTIAL NEPHRECTOMYSivarajan G, Taksler G, Walter D, Bjurlin M, Gross C, Makarov D. PD17-08 THE EFFECT OF THE SURGICAL ROBOT ON THE HOSPITAL-LEVEL UTILIZATION OF PARTIAL NEPHRECTOMY Investigative Urology 2014, 191: e543. DOI: 10.1016/j.juro.2014.02.1515.
  • Stereotactic body radiosurgery versus intensity modulated radiotherapy for prostate cancer: Comparison of toxicity.Yu J, Cramer L, Herrin J, Soulos P, Potosky A, Gross C. Stereotactic body radiosurgery versus intensity modulated radiotherapy for prostate cancer: Comparison of toxicity. Journal Of Clinical Oncology 2014, 32: 89-89. DOI: 10.1200/jco.2014.32.4_suppl.89.
  • Perceptions of radiation oncologists and urologists on the type of evidence that informs and changes the clinical practice of prostate cancer.Delpe S, Shah N, Tilburt J, Karnes R, Nguyen P, Shuch B, Gross C, Schulam P, Yu J, Ziegenfuss J, Kim S. Perceptions of radiation oncologists and urologists on the type of evidence that informs and changes the clinical practice of prostate cancer. Journal Of Clinical Oncology 2014, 32: 167-167. DOI: 10.1200/jco.2014.32.4_suppl.167.
  • Trends in Radiotherapy After Breast-Conserving Surgery in Elderly Patients with Early-Stage Breast Cancer Luu C, Goldstein L, Goldner B, et al (Harbor-UCLA Med Ctr, Torrance, CA; City of Hope Natl Cancer Ctr, Duarte, CA) Ann Surg Oncol 20:3266-3273, 2013§Presley C, Gross C. Trends in Radiotherapy After Breast-Conserving Surgery in Elderly Patients with Early-Stage Breast Cancer Luu C, Goldstein L, Goldner B, et al (Harbor-UCLA Med Ctr, Torrance, CA; City of Hope Natl Cancer Ctr, Duarte, CA) Ann Surg Oncol 20:3266-3273, 2013§ Breast Diseases A Year Book Quarterly 2014, 25: 85-87. DOI: 10.1016/j.breastdis.2014.01.005.
  • Abstract S3-03: Randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer: The hormones and physical exercise (HOPE) studyIrwin M, Cartmel B, Gross C, Ercolano E, Fiellin M, Capozza S, Rothbard M, Zhou Y, Harrigan M, Sanft T, Schmitz K, Neogi T, Hershman D, Ligibel J. Abstract S3-03: Randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer: The hormones and physical exercise (HOPE) study Cancer Research 2013, 73: s3-03-s3-03. DOI: 10.1158/0008-5472.sabcs13-s3-03.
  • Abstract P2-11-22: The use and influence of a 21 gene rearrangement assay in breast cancer: Clinical and pathologic predictors of recurrence score and chemotherapy receiptRutter C, Mancini B, Gross C, Aminawung J, Chagpar A, Saglam O, Hofstatter E, Abu-Khalaf M, Evans S. Abstract P2-11-22: The use and influence of a 21 gene rearrangement assay in breast cancer: Clinical and pathologic predictors of recurrence score and chemotherapy receipt Cancer Research 2013, 73: p2-11-22-p2-11-22. DOI: 10.1158/0008-5472.sabcs13-p2-11-22.
  • Abstract P6-06-09: Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction?Abu-Khalaf M, Medic I, Hatzis C, Park E, Chung G, DiGiovanna M, Hofstatter E, Sanft T, Pusztai L, Gross C, Russell K, Russell R. Abstract P6-06-09: Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction? Cancer Research 2013, 73: p6-06-09-p6-06-09. DOI: 10.1158/0008-5472.sabcs13-p6-06-09.
  • Abstract P6-07-05: Regional variation in Medicare expenditures for older women with localized breast cancerXu X, Soulos P, Herrin J, Ross J, Saraf A, Roberts K, Killelea B, Wang S, Long J, Wang R, Ma X, Gross C. Abstract P6-07-05: Regional variation in Medicare expenditures for older women with localized breast cancer Cancer Research 2013, 73: p6-07-05-p6-07-05. DOI: 10.1158/0008-5472.sabcs13-p6-07-05.
  • Factors associated with unplanned breast cancer readmissions.Gavankar C, Gross C, Lilenbaum R, Chagpar A. Factors associated with unplanned breast cancer readmissions. Journal Of Clinical Oncology 2013, 31: 131-131. DOI: 10.1200/jco.2013.31.31_suppl.131.
  • Accuracy of Point-of-Care Ultrasound for Hydronephrosis in Patients With Suspected Renal Colic: A Look at Emergency Providers With Variable Ultrasound ExperienceHerbst M, Rosenberg G, Daniels B, Gross C, Singh D, Molinaro A, Luty S, Moore C. Accuracy of Point-of-Care Ultrasound for Hydronephrosis in Patients With Suspected Renal Colic: A Look at Emergency Providers With Variable Ultrasound Experience Annals Of Emergency Medicine 2013, 62: s32-s33. DOI: 10.1016/j.annemergmed.2013.07.369.
  • Stereotactic Radiosurgery Versus Intensity Modulated Radiation Therapy for Prostate Cancer: Comparison of Early ToxicityYu J, Cramer L, Herrin J, Soulos P, Potosky A, Gross C. Stereotactic Radiosurgery Versus Intensity Modulated Radiation Therapy for Prostate Cancer: Comparison of Early Toxicity International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s153-s154. DOI: 10.1016/j.ijrobp.2013.06.396.
  • Changes in Early- and Late-Stage Colorectal Cancer Incidence During the Era of Screening: 1976-2009Yang D, Gross C, Yu J. Changes in Early- and Late-Stage Colorectal Cancer Incidence During the Era of Screening: 1976-2009 International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s331. DOI: 10.1016/j.ijrobp.2013.06.872.
  • The Dissemination of New Technologies and Temporal Trends in Curative Therapy for Prostate Cancer Patients With Low Likelihood of Clinical BenefitRaldow A, Presley C, Yu J, Cramer L, Soulos P, Long J, Makarov D, Gross C. The Dissemination of New Technologies and Temporal Trends in Curative Therapy for Prostate Cancer Patients With Low Likelihood of Clinical Benefit International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s177-s178. DOI: 10.1016/j.ijrobp.2013.06.459.
  • For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery.Sen S, Soulos P, Herrin J, Roberts K, Yu J, Lesnikoski B, Ross J, Krumholz H, Gross C. For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery. Journal Of Clinical Oncology 2013, 31: 6511-6511. DOI: 10.1200/jco.2013.31.15_suppl.6511.
  • The cost implications of prostate cancer screening in the Medicare population.Ma X, Wang R, Long J, Ross J, Soulos P, Yu J, Makarov D, Gold H, Gross C. The cost implications of prostate cancer screening in the Medicare population. Journal Of Clinical Oncology 2013, 31: 6549-6549. DOI: 10.1200/jco.2013.31.15_suppl.6549.
  • Health practices and behaviors of childhood cancer survivors not attending a comprehensive survivor clinic.Iyer N, Mitchell H, Gross C, Ma X, Kadan-Lottick N. Health practices and behaviors of childhood cancer survivors not attending a comprehensive survivor clinic. Journal Of Clinical Oncology 2013, 31: 10063-10063. DOI: 10.1200/jco.2013.31.15_suppl.10063.
  • Changes in early- and late-stage colorectal cancer incidence during the era of screening: 1976-2009.Yang D, Gross C, Yu J. Changes in early- and late-stage colorectal cancer incidence during the era of screening: 1976-2009. Journal Of Clinical Oncology 2013, 31: 1522-1522. DOI: 10.1200/jco.2013.31.15_suppl.1522.
  • Measures of polypharmacy and chemotherapy toxicity in older adults with cancer.Maggiore R, Feng T, Dale W, Gross C, Tew W, Mohile S, Owusu C, Klepin H, Lichtman S, Gajra A, McKoy J, Katheria V, Ramani R, Jayani R, Brown J, Hurria A. Measures of polypharmacy and chemotherapy toxicity in older adults with cancer. Journal Of Clinical Oncology 2013, 31: 9545-9545. DOI: 10.1200/jco.2013.31.15_suppl.9545.
  • The Cost of Breast Cancer Screening in the Medicare PopulationGross CP, Long JB, Ross JS, Abu-Khalaf MM, Wang R, Killelea BK, Gold HT, Chagpar AB, Ma X. The Cost of Breast Cancer Screening in the Medicare Population JAMA Internal Medicine 2013, 173: 220-226. PMID: 23303200, PMCID: PMC3638736, DOI: 10.1001/jamainternmed.2013.1397.
  • Use of Hospital-Based Acute Care Among Patients Recently Discharged From the HospitalVashi AA, Fox JP, Carr BG, D’Onofrio G, Pines JM, Ross JS, Gross CP. Use of Hospital-Based Acute Care Among Patients Recently Discharged From the Hospital JAMA 2013, 309: 364-371. PMID: 23340638, PMCID: PMC3598620, DOI: 10.1001/jama.2012.216219.
  • Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early ToxicityYu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP. Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity Journal Of The National Cancer Institute 2012, 105: 25-32. PMID: 23243199, PMCID: PMC3536640, DOI: 10.1093/jnci/djs463.
  • Proton Radiation Therapy for Prostate Cancer in the Medicare Population: Patterns of Care and Comparison of Early Toxicity With Intensity Modulated Radiation TherapyYu J, Soulos P, Herrin J, Cramer L, Potosky A, Roberts K, Gross C. Proton Radiation Therapy for Prostate Cancer in the Medicare Population: Patterns of Care and Comparison of Early Toxicity With Intensity Modulated Radiation Therapy International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s13. DOI: 10.1016/j.ijrobp.2012.07.040.
  • Understanding Costs and Value of Newer Radiation Modalities Among Older Women With Breast CancerSen S, Soulos P, Frick K, Long J, Roberts K, Yu J, Evans S, Chagpar A, Gross C. Understanding Costs and Value of Newer Radiation Modalities Among Older Women With Breast Cancer International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s35. DOI: 10.1016/j.ijrobp.2012.07.096.
  • Temporal Trends in Radiation Modalities Among Older Women With Favorable Risk Breast CancerRoberts K, Soulos P, Yu J, Evans S, Long J, Gross C. Temporal Trends in Radiation Modalities Among Older Women With Favorable Risk Breast Cancer International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s34. DOI: 10.1016/j.ijrobp.2012.07.093.
  • Comparison of the Level of Evidence Supporting Practice Guidelines in Cancer Care Between Therapeutic ModalitiesBuscariollo D, Lloyd S, Gross C, Makarov D, Yu J. Comparison of the Level of Evidence Supporting Practice Guidelines in Cancer Care Between Therapeutic Modalities International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s43. DOI: 10.1016/j.ijrobp.2012.07.324.
  • The Funding of Phase III Clinical Trials Examining Radiation Compared With That of Other ModalitiesLloyd S, Buscariollo D, Gross C, Makarov D, Yu J, Aneja S. The Funding of Phase III Clinical Trials Examining Radiation Compared With That of Other Modalities International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s44-s45. DOI: 10.1016/j.ijrobp.2012.07.326.
  • Laparoscopic colon resection for cancer is not associated with fewer hospital-based encounters following dischargeHansen D, Fox J, Gross C, Bruun J. Laparoscopic colon resection for cancer is not associated with fewer hospital-based encounters following discharge Journal Of The American College Of Surgeons 2012, 215: s99. DOI: 10.1016/j.jamcollsurg.2012.06.264.
  • Aromatase inhibitors, arthralgias, and exercise in breast cancer survivors.Irwin M, Cartmel B, Ercolano E, Fiellin M, Rothbard M, Capozza S, Zhou Y, Schmitz K, Ligibel J, Hershman D, Neogi T, Gross C. Aromatase inhibitors, arthralgias, and exercise in breast cancer survivors. Journal Of Clinical Oncology 2012, 30: tps669-tps669. DOI: 10.1200/jco.2012.30.15_suppl.tps669.
  • The evolution of breast cancer screening in the Medicare population: Clinical and economic implications.Killelea B, Long J, Ma X, Wang R, Chagpar A, Ross J, Gross C. The evolution of breast cancer screening in the Medicare population: Clinical and economic implications. Journal Of Clinical Oncology 2012, 30: 1595-1595. DOI: 10.1200/jco.2012.30.15_suppl.1595.
  • Short-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009.Presley C, Soulos P, Herrin J, Roberts K, Yu J, Killelea B, Lesnikoski B, Long J, Gross C. Short-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009. Journal Of Clinical Oncology 2012, 30: 1030-1030. DOI: 10.1200/jco.2012.30.15_suppl.1030.
  • Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT.Yu J, Soulos P, Cramer L, Roberts K, Herrin J, Potosky A, Gross C. Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT. Journal Of Clinical Oncology 2012, 30: 4651-4651. DOI: 10.1200/jco.2012.30.15_suppl.4651.
  • Regional variation in treatment costs and survival for elderly patients with myelodysplastic syndromes.Ma X, Wang R, Long J, Gold H, Halene S, Gross C. Regional variation in treatment costs and survival for elderly patients with myelodysplastic syndromes. Journal Of Clinical Oncology 2012, 30: 6628-6628. DOI: 10.1200/jco.2012.30.15_suppl.6628.
  • An assessment of the collective efforts of clinical trials to provide evidence-based practice guidelines in cancer care.Lloyd S, Buscariollo D, Gross C, Makarov D, Yu J. An assessment of the collective efforts of clinical trials to provide evidence-based practice guidelines in cancer care. Journal Of Clinical Oncology 2012, 30: 6019-6019. DOI: 10.1200/jco.2012.30.15_suppl.6019.
  • Factors associated with life expectancy (LE) < 3 months (mo) among older adults receiving palliative chemotherapy (chemo).Hurria A, Hardt M, Tew W, Mohile S, Owusu C, Gross C, Gajra A, Lichtman S, Katheria V, Ramani R, Zavala L, Klepin H. Factors associated with life expectancy (LE) < 3 months (mo) among older adults receiving palliative chemotherapy (chemo). Journal Of Clinical Oncology 2012, 30: 9034-9034. DOI: 10.1200/jco.2012.30.15_suppl.9034.
  • Anemia and functional disability in older adults with cancer.Owusu C, Tew W, Hardt M, Mohile S, Klepin H, Gross C, Gajra A, Lichtman S, Ramani R, Katheria V, Zavala L, Hurria A. Anemia and functional disability in older adults with cancer. Journal Of Clinical Oncology 2012, 30: 9109-9109. DOI: 10.1200/jco.2012.30.15_suppl.9109.
  • The relationship among age, anxiety, and depression in older adults with cancer.Weiss T, Nelson C, Tew W, Hardt M, Mohile S, Owusu C, Klepin H, Gross C, Gajra A, Lichtman S, Ramani R, Katheria V, Zavala L, Hurria A. The relationship among age, anxiety, and depression in older adults with cancer. Journal Of Clinical Oncology 2012, 30: 9123-9123. DOI: 10.1200/jco.2012.30.15_suppl.9123.
  • The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population.Quon J, Yu J, Soulos P, Gross C. The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population. Journal Of Clinical Oncology 2012, 30: e15150-e15150. DOI: 10.1200/jco.2012.30.15_suppl.e15150.
  • Predictors of early discontinuation of chemotherapy (EDC) in patients (pts) age 65 or older with stage IV non-small cell lung cancer (NSCLC).Gajra A, Tew W, Hardt M, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Katheria V, Hurria A. Predictors of early discontinuation of chemotherapy (EDC) in patients (pts) age 65 or older with stage IV non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2012, 30: e18133-e18133. DOI: 10.1200/jco.2012.30.15_suppl.e18133.
  • 419 FACTORS ASSOCIATED WITH THE EARLY ACQUISITION OF THE SURGICAL ROBOT BY HOSPITALS IN THE UNITED STATESMakarov D, Li H, Yu J, Makary M, Braithwaite S, Sherman S, Taneja S, Penson D, Lepor H, Desai R, Blustein J, Gross C. 419 FACTORS ASSOCIATED WITH THE EARLY ACQUISITION OF THE SURGICAL ROBOT BY HOSPITALS IN THE UNITED STATES Investigative Urology 2012, 187: e172. DOI: 10.1016/j.juro.2012.02.485.
  • Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare PopulationSoulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP. Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population Journal Of Clinical Oncology 2012, 30: 1601-1607. PMID: 22393088, PMCID: PMC3383112, DOI: 10.1200/jco.2011.39.4890.
  • RISK OF HEART FAILURE OR CARDIOMYOPATHY ASSOCIATED WITH ADJUVANT TRASTUZUMAB OR CHEMOTHERAPY IN OLDER WOMEN WITH BREAST CANCERChen J, Long J, Steingart R, Gross C. RISK OF HEART FAILURE OR CARDIOMYOPATHY ASSOCIATED WITH ADJUVANT TRASTUZUMAB OR CHEMOTHERAPY IN OLDER WOMEN WITH BREAST CANCER Journal Of The American College Of Cardiology 2012, 59: e996. DOI: 10.1016/s0735-1097(12)60997-8.
  • The influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit.Yu J, Aneja S, Makarov D, Roberts K, Gross C. The influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit. Journal Of Clinical Oncology 2012, 30: 19-19. DOI: 10.1200/jco.2012.30.5_suppl.19.
  • The influence of regional radiation oncologist and urologist capacities on treatment choice for prostate cancer management.Yu J, Aneja S, Makarov D, Roberts K, Gross C. The influence of regional radiation oncologist and urologist capacities on treatment choice for prostate cancer management. Journal Of Clinical Oncology 2012, 30: 108-108. DOI: 10.1200/jco.2012.30.5_suppl.108.
  • Reply to J. Lagro et alHurria A, Togawa K, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong F, Tew W. Reply to J. Lagro et al Journal Of Clinical Oncology 2012, 30: 561-562. DOI: 10.1200/jco.2011.39.5319.
  • The Influence of Regional Radiation Oncologist and Urologist Capacities on Treatment Choice for Prostate CancerAneja S, Gross C, Makarov D, Roberts K, Yu J. The Influence of Regional Radiation Oncologist and Urologist Capacities on Treatment Choice for Prostate Cancer International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s552. DOI: 10.1016/j.ijrobp.2011.06.869.
  • Are the Efforts of Current Clinical Trials Involving Radiation Therapy Focused on the Evidence Gaps in Cancer Treatment?Lloyd S, Gross C, Makarov D, Yu J. Are the Efforts of Current Clinical Trials Involving Radiation Therapy Focused on the Evidence Gaps in Cancer Treatment? International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s139-s140. DOI: 10.1016/j.ijrobp.2011.06.286.
  • The Influence of Physician Densities and Patient Characteristics on the Decision to Treat Prostate Cancer Patients with Varying Clinical BenefitAneja S, Makarov D, Gross C, Roberts K, Yu J. The Influence of Physician Densities and Patient Characteristics on the Decision to Treat Prostate Cancer Patients with Varying Clinical Benefit International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s553. DOI: 10.1016/j.ijrobp.2011.06.871.
  • Do cancer survivors follow screening guidelines better?Chagpar A, Sanft T, Gross C. Do cancer survivors follow screening guidelines better? Journal Of Clinical Oncology 2011, 29: 1597-1597. DOI: 10.1200/jco.2011.29.15_suppl.1597.
  • Racial disparities in prostate cancer treatment: The contribution of inappropriate care.Presley C, Raldow A, Cramer L, Soulos P, Long J, Makarov D, Yu J, Gross C. Racial disparities in prostate cancer treatment: The contribution of inappropriate care. Journal Of Clinical Oncology 2011, 29: 4544-4544. DOI: 10.1200/jco.2011.29.15_suppl.4544.
  • Predictors of primary dose reduction (PDR) among patients (pts) age 65 and older receiving adjuvant chemotherapy (chemo).Klepin H, Gajra A, Hardt M, Tew W, Mohile S, Owusu C, Gross C, Lichtman S, Ramani R, Katheria V, Brown J, Jayani R, Hansen K, Togawa K, Klapper S, Wong F, Hurria A. Predictors of primary dose reduction (PDR) among patients (pts) age 65 and older receiving adjuvant chemotherapy (chemo). Journal Of Clinical Oncology 2011, 29: 9003-9003. DOI: 10.1200/jco.2011.29.15_suppl.9003.
  • Primary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts) older than age 65 with advanced cancer (Ca) and toxicity outcomes.Gajra A, Hardt M, Tew W, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Ramani R, Brown J, Katheria V, Jayani R, Hansen K, Togawa K, Klapper S, Hurria A. Primary dose reduction (PDR) of chemotherapy (chemo) in patients (Pts) older than age 65 with advanced cancer (Ca) and toxicity outcomes. Journal Of Clinical Oncology 2011, 29: 9037-9037. DOI: 10.1200/jco.2011.29.15_suppl.9037.
  • Polypharmacy, potentially inappropriate medications, and chemotherapy-related adverse events among older adults with cancer.Maggiore R, Gross C, Hardt M, Tew W, Mohile S, Klepin H, Lichtman S, Owusu C, Gajra A, Ramani R, Katheria V, Brown J, Jayani R, Hurria A. Polypharmacy, potentially inappropriate medications, and chemotherapy-related adverse events among older adults with cancer. Journal Of Clinical Oncology 2011, 29: e19501-e19501. DOI: 10.1200/jco.2011.29.15_suppl.e19501.
  • Adoption Of Invasive Clinical Staging Techniques In Stage IIIA Non-Small Cell Lung Cancer Lags Adoption Of Positron Emission TomographyVest M, Tanoue L, Soulos P, Kim A, Gross C. Adoption Of Invasive Clinical Staging Techniques In Stage IIIA Non-Small Cell Lung Cancer Lags Adoption Of Positron Emission Tomography 2011, a5380-a5380. DOI: 10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5380.
  • 439 THE ASSOCIATION BETWEEN DIFFUSION OF THE SURGICAL ROBOT AND RADICAL PROSTATECTOMY RATESMakarov D, Yu J, Desai R, Penson D, Gross C. 439 THE ASSOCIATION BETWEEN DIFFUSION OF THE SURGICAL ROBOT AND RADICAL PROSTATECTOMY RATES Investigative Urology 2011, 185: e178-e179. DOI: 10.1016/j.juro.2011.02.530.
  • 443 REGIONAL VARIATION IN THE COST OF RADICAL CYSTECTOMY: EVIDENCE FROM THE HEALTHCARE COST AND UTILIZATION PROJECT NATIONWIDE INPATIENT SAMPLEHemani M, Huang W, Blustein J, Braithwaite S, Sherman S, Gross C, Taneja S, Penson D, Desai R, Makarov D. 443 REGIONAL VARIATION IN THE COST OF RADICAL CYSTECTOMY: EVIDENCE FROM THE HEALTHCARE COST AND UTILIZATION PROJECT NATIONWIDE INPATIENT SAMPLE Investigative Urology 2011, 185: e180-e181. DOI: 10.1016/j.juro.2011.02.534.
  • Head and Neck Cancer (HNC) Patients Undergoing Intensity Modulated Radiation Therapy (IMRT) Have Fewer Subsequent Days of Hospitalization (DOH) than Do Patients Undergoing Conventional Radiation Therapy (CRT) in the SEER-Medicare Linked DatabaseGross C, Soulos P, Sharma R, Makarov D, Decker R, Smith B, Desai R, Cramer L, Yu J. Head and Neck Cancer (HNC) Patients Undergoing Intensity Modulated Radiation Therapy (IMRT) Have Fewer Subsequent Days of Hospitalization (DOH) than Do Patients Undergoing Conventional Radiation Therapy (CRT) in the SEER-Medicare Linked Database International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s445. DOI: 10.1016/j.ijrobp.2010.07.1045.
  • Head and Neck Cancer (HNC) Patients Undergoing Primary Radiation with Intensity Modulated Radiation Therapy (IMRT) Demonstrate Improved Overall Survival (OS) Compared to Those Undergoing Conventional Radiation Therapy (CRT) in the SEER-Medicare Linked DatabaseYu J, Soulos P, Sharma R, Makarov D, Decker R, Smith B, Desai R, Cramer L, Gross C. Head and Neck Cancer (HNC) Patients Undergoing Primary Radiation with Intensity Modulated Radiation Therapy (IMRT) Demonstrate Improved Overall Survival (OS) Compared to Those Undergoing Conventional Radiation Therapy (CRT) in the SEER-Medicare Linked Database International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s459. DOI: 10.1016/j.ijrobp.2010.07.1077.
  • Temporal Trends in the Treatment of Elderly Men with Low and Moderate Risk Prostate Cancer: The Effect of Life Expectancy on the Administration of Curative TherapyRaldow A, Sharma R, Presley C, Cramer L, Yu J, Soulos P, Gross C. Temporal Trends in the Treatment of Elderly Men with Low and Moderate Risk Prostate Cancer: The Effect of Life Expectancy on the Administration of Curative Therapy International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s562. DOI: 10.1016/j.ijrobp.2010.07.1312.
  • 221: Current Strategies and Future Solutions to On-Call Care ShortagesRao M, Lerro C, Gross C. 221: Current Strategies and Future Solutions to On-Call Care Shortages Annals Of Emergency Medicine 2010, 56: s73. DOI: 10.1016/j.annemergmed.2010.06.269.
  • Predicting chemotherapy toxicity in older adults with cancer: A prospective 500 patient multicenter study.Hurria A, Togawa K, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Katheria V, Klapper S, Tew W. Predicting chemotherapy toxicity in older adults with cancer: A prospective 500 patient multicenter study. Journal Of Clinical Oncology 2010, 28: 9001-9001. DOI: 10.1200/jco.2010.28.15_suppl.9001.
  • Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients.Gibney G, Elfiky A, Hoimes C, Burns A, Rowen E, McDonough J, Lampert R, Gross C, Kelly W. Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients. Journal Of Clinical Oncology 2010, 28: tps244-tps244. DOI: 10.1200/jco.2010.28.15_suppl.tps244.
  • S1147 Effect of Gender, Age, and Life Expectancy on Receipt of Screening Colonoscopy in the Medicare PopulationGancayco J, Khiani V, Soulos P, Cramer L, Ross J, Braithwaite S, Genao I, Tinetti M, Gross C. S1147 Effect of Gender, Age, and Life Expectancy on Receipt of Screening Colonoscopy in the Medicare Population Gastroenterology 2010, 138: s-190. DOI: 10.1016/s0016-5085(10)60863-3.
  • 270 INAPPROPRIATE USE OF IMAGING TO STAGE INCIDENT PROSTATE CANCER IN THE MEDICARE POPULATIONMakarov D, Sharma R, Yu J, Abraham N, Desai R, Albertsen P, Penson D, Gross C. 270 INAPPROPRIATE USE OF IMAGING TO STAGE INCIDENT PROSTATE CANCER IN THE MEDICARE POPULATION Investigative Urology 2010, 183: e106-e107. DOI: 10.1016/j.juro.2010.02.330.
  • Predicting the Extent of Prostate CancerYu J, Makarov D, Gross C. Predicting the Extent of Prostate Cancer International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s313-s314. DOI: 10.1016/j.ijrobp.2009.07.719.
  • Geriatric assessment of older adults with cancer: Baseline data from a 500 patient multicenter studyHurria A, Mohile S, Lichtman S, Owusu C, Klepin H, Gross C, Hansen K, Klapper S, Togawa K, Tew W. Geriatric assessment of older adults with cancer: Baseline data from a 500 patient multicenter study Journal Of Clinical Oncology 2009, 27: 9546-9546. DOI: 10.1200/jco.2009.27.15_suppl.9546.
  • VALIDATING THE PARTIN TABLES USING THE NCI SEER DATABASEYu J, Makarov D, Sharma R, Peschel R, Partin A, Gross C. VALIDATING THE PARTIN TABLES USING THE NCI SEER DATABASE Investigative Urology 2009, 181: 170. DOI: 10.1016/s0022-5347(09)60487-0.
  • Survey of Radiosurgery Practitioner Attitudes on the use of Stereotactic Radiosurgery Alone for Oligometastatic Brain MetastasesKnisely J, Gross C, Castrucci W, Chiang V. Survey of Radiosurgery Practitioner Attitudes on the use of Stereotactic Radiosurgery Alone for Oligometastatic Brain Metastases International Journal Of Radiation Oncology • Biology • Physics 2008, 72: s241-s242. DOI: 10.1016/j.ijrobp.2008.06.625.
  • Life Expectancy and Colorectal Cancer ScreeningGross C, McAvay G, Tinetti M. Life Expectancy and Colorectal Cancer Screening Annals Of Internal Medicine 2007, 146: 758. DOI: 10.7326/0003-4819-146-10-200705150-00018.
  • The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening.Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Annals Of Internal Medicine 2006, 145: 646-53. PMID: 17088577, DOI: 10.7326/0003-4819-145-9-200611070-00006.
  • The relation between projected breast cancer risk, perceived cancer risk, and mammography useGross C, Filardo G, Singh H, Freedman A, Farrell M. The relation between projected breast cancer risk, perceived cancer risk, and mammography use Journal Of General Internal Medicine 2006, 21: 158-164. DOI: 10.1007/s11606-006-0251-4.
  • Cancer Trial Enrollment After State-Mandated ReimbursementGross C, Murthy V, Li Y, Kaluzny A, Krumholz H. Cancer Trial Enrollment After State-Mandated Reimbursement Investigative Urology 2006, 175: 265. DOI: 10.1016/s0022-5347(05)00074-1.
  • Are Racial and Ethnic Minorities Less Willing to Participate in Health Research?Wendler D, Kington R, Madans J, Van Wye G, Christ-Schmidt H, Pratt LA, Brawley OW, Gross CP, Emanuel E. Are Racial and Ethnic Minorities Less Willing to Participate in Health Research? PLOS Medicine 2005, 3: e19. PMID: 16318411, PMCID: PMC1298944, DOI: 10.1371/journal.pmed.0030019.
  • Disparities in Participation in Cancer Clinical Trials—ReplyMurthy V, Krumholz H, Gross C. Disparities in Participation in Cancer Clinical Trials—Reply JAMA 2004, 292: 922-922. DOI: 10.1001/jama.292.8.922-b.
  • Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based DisparitiesMurthy VH, Krumholz HM, Gross CP. Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities JAMA 2004, 291: 2720-2726. PMID: 15187053, DOI: 10.1001/jama.291.22.2720.
  • 838-1 National patterns of spironolactone prescription for older patients with heart failure and left ventricular systolic dysfunction before and after RALESMasoudi F, Gross C, Wang Y, Havranek E, Rathore S, Foody J, Krumholz H. 838-1 National patterns of spironolactone prescription for older patients with heart failure and left ventricular systolic dysfunction before and after RALES Journal Of The American College Of Cardiology 2004, 43: a415. DOI: 10.1016/s0735-1097(04)91750-0.
  • Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic ReviewBekelman JE, Li Y, Gross CP. Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review JAMA 2003, 289: 454-465. PMID: 12533125, DOI: 10.1001/jama.289.4.454.
  • Factors Affecting Prophylactic Oophorectomy in Postmenopausal WomenGROSS C, NICHOLSON W, POWE N. Factors Affecting Prophylactic Oophorectomy in Postmenopausal Women Obstetrics And Gynecology 1999, 94: 962-968. PMID: 10576183, DOI: 10.1097/00006250-199912000-00011.
  • Management of Barrett's esophagus: a national study of practice patterns and their cost implicationsGross C, Canto M, Hixson J, Powe N. Management of Barrett's esophagus: a national study of practice patterns and their cost implications The American Journal Of Gastroenterology 1999, 94: ajg1999806. PMID: 10606300, DOI: 10.1111/j.1572-0241.1999.01606.x.
  • The Relation between Funding by the National Institutes of Health and the Burden of DiseaseGross C, Anderson G, Powe N. The Relation between Funding by the National Institutes of Health and the Burden of Disease New England Journal Of Medicine 1999, 340: 1881-1887. PMID: 10369852, DOI: 10.1056/nejm199906173402406.
  • The Physician as Ambivalent SamaritanGross C, Reisman A, Schwartz M. The Physician as Ambivalent Samaritan Journal Of General Internal Medicine 1998, 13: 491-494. PMID: 9686718, PMCID: PMC1496980, DOI: 10.1046/j.1525-1497.1998.00141.x.
  • The myth of the medical breakthrough: Smallpox, vaccination, and Jenner reconsideredGross C, Sepkowitz K. The myth of the medical breakthrough: Smallpox, vaccination, and Jenner reconsidered International Journal Of Infectious Diseases 1998, 3: 54-60. PMID: 9831677, DOI: 10.1016/s1201-9712(98)90096-0.
Edit Profile